documents incorporated reference portions proxy statement filed march part iiiexplanatory note company restating consolidated balance sheet december consolidated statements earnings cash flows comprehensive income retained earnings years ended december restatement restatement affected periods prior impact restatement prior periods reflected adjustment opening retained earnings january restatement reported annual report year ended december reported amendments quarterly reports form q quarterly periods ended march june september restatement corrects certain companys historical accounting policies conform generally accepted accounting principles gaap ii corrects certain errors made application gaap including revision inappropriate accounting respect companys accounting tax contingency reserves restatement includes adjustments earnings continuing operations minority interest income taxes ii minority interest net taxes iii provision income taxes iv earnings discontinued operations v cash cash equivalents restatement adjustments increased companys net earnings diluted earnings per share year ended december approximately million per share reduced net earnings diluted earnings per share year ended december approximately million per share restatement adjustment companys consolidated balance sheet decreased amount cash cash equivalents december approximately billion increased marketable securities amount consolidated balance sheet december restated cash cash equivalents would decrease approximately billion marketable securities increased amount restatement adjustment statements cash flows increased amount net cash used investing activities years ended december approximately billion billion respectively impact periods prior discussion individual restatement adjustments see item financial statementsnote restatement previously issued financial statements years ended december additionally see item managements discussion analysis financial condition results operations information impact restatement years see item selected financial data part ii report company amend annual report quarterly reports form q periods affected restatement ended prior march financial statements related financial information contained reports longer relied upon referenced amounts annual report prior periods prior period comparisons reflect balances amounts restated basis part item business general bristolmyers squibb company may referred bristolmyers squibb bms company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger company divisions subsidiaries engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals healthcare related products acquisitions divestitures october company acquired dupont pharmaceuticals business dupont pharmaceuticals ei du pont de nemours company billion cash dupont pharmaceuticals primarily domestic pharmaceutical imaging product business focused research development addition november company purchased million shares imclone systems incorporated imclone per share million represented shares outstanding prior companys commencement public tender offer imclone shares equity investment imclone part strategic agreement company imclone also includes arrangement codevelop copromote cancer drug erbitux transactions financed proceeds issuance billion commercial paper issuance billion mediumterm notes internal cash flows part companys strategy focus pharmaceutical healthcare businesses company decided divest clairol zimmer businesses accordingly operations businesses reflected discontinued operations accompanying consolidated financial statements november company completed sale clairol billion august company spun zimmer holdings inc taxfree distribution bristolmyers squibb website companys internet website address wwwbmscom company makes available free charge website annual quarterly current reports including amendments reports soon reasonably practicable company electronically files material furnishes material securities exchange commission information relating corporate governance bristolmyers squibb including companys corporate governance guidelines standards business conduct ethics code ethics senior financial officers information concerning companys executive committee board directors board committees including committee charters transactions bristolmyers squibb securities directors officers available companys website wwwbmscom investorscorporate governance caption waivers material amendments code ethics posted promptly companys website information relating stockholder services including companys dividend reinvestment plan direct deposit dividends available companys website wwwbmscom investorsstockholder services caption company incorporates reference certain information parts proxy statement annual meeting stockholders sec allows company disclose important information referring manner please refer information companys proxy statement annual meeting stockholders annual report available companys website wwwbmscom investorssec filings caption business segments company four reportable segmentspharmaceuticals oncology therapeutics network otn nutritionals healthcare pharmaceuticals segment made global pharmaceutical international excluding japan consumer medicines business otn segment provides oncology products supportive care products related supplies officebased oncologists united states nutritionals segment consists mead johnson nutritionals mead johnson primarily infant formula business healthcare segment consists convatec medical imaging consumer medicines north america japan businesses additional information segments see item financial statementsnote segment information pharmaceuticals segment pharmaceuticals segment discovers develops licenses manufactures markets distributes sells branded pharmaceuticals products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession company manufactures products united states puerto rico fifteen foreign countries pharmaceuticals sales accounted approximately companys sales companys sales domestic pharmaceuticals sales accounted total pharmaceuticals sales total pharmaceuticals sales total pharmaceuticals sales pharmaceuticals sales europe accounted total pharmaceuticals sales total pharmaceuticals sales total pharmaceuticals sales pharmaceuticals sales japan accounted total pharmaceuticals sales years companys strategy build pipeline support sustainable growth focusing discovery development efforts ten disease areas increasing sales marketing emphasis specialists high value primary care prescribers investing research development establishing biologics business addition discovering developing products research development efforts company actively pursues products research collaborations strategic alliances others pharmaceutical industry additional information see strategic alliances research development pharmaceuticals segment competes worldwide researchbased drug companies smaller research companies generic drug manufacturers company expects lose certain revenues next several years result expiration market exclusivity protection certain products also believes revenue loss less offset growth inline products including recently launched products subject regulatory approval introduction latestage pipeline products however revenues could negatively impacted competitive factors including relating pravachol outcome plavix litigation information matters see products competition research development item managements discussion analysis financial condition results operationsoutlook item financial statementsnote legal proceedings contingencies products companys pharmaceutical revenues come products following therapeutic classes cardiovascular metabolic oncology infectious diseases including human immunodeficiency virusacquired immune deficiency syndrome hivaids affective psychiatric disorders pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity market exclusivity based upon patent rights andor certain regulatory forms exclusivity patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product companys business focused innovative pharmaceutical products company relies patent rights forms protection maintain market exclusivity products discussion patents rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition companys business see generic competition chart shows net sales key products pharmaceuticals segment together year basic exclusivity loss patent rights data exclusivity occurred expected occur united states european union eu japan company also sells pharmaceutical products countries however data provided countrybycountry basis individual country sales significant outside united states eu japan instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval company assesses market exclusivity period products casebycase basis length market exclusivity companys products difficult predict certainty complex interaction patent regulatory forms exclusivity factors assurance particular product enjoy market exclusivity full period time company currently anticipates past past past currently currently currently expected expected expected year year year eu japanese us basic basic basic restated restated exclusivity exclusivity exclusivity pharmaceutical product loss lossa loss dollars millions pravachol plavix taxol paraplatin avaproavalide sustiva monopril glucovance glucophage xr zeritzerit er coumadin b abilify videxvidex ec tequin glucophage ir serzone reyataz buspar note currently expected year basic exclusivity loss includes statutory extensions exclusivity earned speculative instances may laterexpiring patents cover particular forms compositions drug well methods manufacture methods using drug patents may sometimes result favorable market position companys product product exclusivity beyond date specified predicted assured company currently market product jurisdiction indicated references eu throughout include following current member states austria belgium denmark finland france germany greece ireland italy luxembourg netherlands portugal spain sweden united kingdom instances date basic exclusivity loss different various eu member states instances earliest latest dates basic exclusivity loss listed eu countries basic patent obtained may data protection available b eu basic exclusivity expired bms acquired product summary indication intellectual property position licensing arrangements thirdparty manufacturing arrangements products united states applicable eu japan pravachol pravastatin sodium cardiovascular product hmg coa reductase inhibitor indicated adjunct diet patients primary hypercholesterolemia lowering risk first heart attack people without clinically evident coronary heart disease elevated cholesterol reducing risk heart attack stroke patients clinically evident coronary heart disease company licensed patent covering pravastatin sankyo company ltd japan sankyo april terms license company may market sell pravastatin throughout world excluding japan korea taiwan thailand markets sankyo retains exclusive patent rights sankyo also comarkets pravastatin certain european countries composition matter patent scheduled expire united states october extended six months april law provides exclusivity extensions pediatric research eu composition matter patent obtained greece luxembourg portugal expired spain july composition matter patent expire august belgium denmark finland germany ireland netherlands united kingdom austria expiration occur november france sweden expiration occur august march respectively italy expiration occur january companys bulk requirements pravastatin supplied sankyo arrangement includes royalty payment based product sales bms finishes product facilities plavix clopidogrel bisulfate cardiovascular product platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel codeveloped jointly marketed sanofisynthelabo sanofi worldwide alliance operates framework two geographic territories one americas australia bmss primary territory europe asia sanofis primary territory two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries country level agreements either copromote whereby partnership formed parties sell single brand comarket whereby parties operate sell brands independently place composition matter patent united states expire includes statutory patent term extension patent currently subject litigation company continues believe patent valid infringed alliance partner patentholder sanofi vigorously pursuing litigation possible time reasonably assess outcome litigation adverse determination litigation timing potential generic competition plavix information litigation see item financial statementsnote legal proceedings contingencies information potential effects generic competition plavix see item managements discussion analysis financial condition results operationsoutlook eu regulatory data exclusivity extends key composition matter patent expire bulk requirements clopidogrel supplied partnership sanofi produces bulk clopidogrel facilities obtains portion bulk clopidogrel requirements third party arrangement includes royalty payments based product sales partnership produces finished product sale information companys arrangements sanofi see strategic alliances item financial statementsnote alliances investments taxol paclitaxel oncology product used treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment aids related kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin paclitaxel developed collaborative research development agreement us government agreement company obtained rights us governments taxol data active ingredient taxol paclitaxel patent protection united states eu japan regulatory protection form data exclusivity data exclusivity united states expired although final marketing approval generic paclitaxel occur january data exclusivity eu expired september data exclusivity taxol japan expired july patent claiming approved dosing administration schedule expires japan numerous factors make impossible predict loss market exclusivity japan actually occur information regarding recently settled litigation involving taxol see item financial statementsnote legal proceedings contingencies company supplied bulk requirements paclitaxel third parties produces finished goods facilities paraplatin carboplatin oncology product chemotherapeutic agent used treatment ovarian cancer company holds exclusive patent license carboplatin research corporation technology rct university michigan company pays royalty based percentage product sales license company rights market paraplatin worldwide patent carboplatin expire united states april company conducting pediatric clinical studies examining carboplatin upon completion studies timely submission results us food drug administration fda company could earn exclusivity extension would extend exclusivity period united states october assurance exclusivity carboplatin extended result studies eu basic patent covering carboplatin obtained france germany netherlands sweden united kingdom last patent expire countries france japan basic patent expired company obtains bulk requirements carboplatin third party produces finished goods facilities avaproavalide irbesartanirbesartanhydrochlorothiazide cardiovascular product angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi companys alliance sanofi operates framework two geographic territories one bmss primary territory sanofis primary territory basic composition matter patent united states expires eu data exclusivity eu expires irbesartan manufactured bristolmyers squibb sanofi bulk irbesartan sold territory joint ventures fixed percentage per kilo intellectual property license arrangements sanofi collects royalty based percentage net sales information companys arrangements sanofi see strategic alliances item financial statementsnote alliances investments sustiva efavirenz virology product antiretroviral drug used treatment hivaids rights market efavirenz united states united kingdom france germany ireland italy spain acquired part dupont pharmaceuticals acquisition completed october rights related product licensed merck co royalty based percentage net sales basic composition matter patent expires united states separate method use patent expires basic composition matter patents united kingdom ireland france germany italy spain expire data exclusivity eu expires company obtains bulk requirements efavirenz third parties produces finished goods facilities monopril fosinopril sodium cardiovascular product secondgeneration angiotensin converting enzyme ace inhibitor oncea day dosing indicated treatment hypertension monopril developed internally basic composition matter patent united states expired june basic composition matter patent expired denmark greece portugal spain october composition matter patent obtained finland rest eu composition matter patent expire countrybycountry basis glucophage ir metformin hydrochlorideglyburide metformin hydrochloride metabolics products oral antidiabetic agents type glucophage xr diabetes glucovance metformin developed merck sant sas merck sant terms arrangement company may market sell metformin united states company purchases bulk metformin price including royalty based percentage net sales data exclusivity glucophage ir expired march regulatory exclusivity expired glucophage xr october glucovance july company earned pediatric exclusivity extension glucovance extended regulatory exclusivity january company obtains bulk requirements metformin merck sant produces finished product facilities zeritzerit er stavudine virology product used treatment hivaids company holds exclusive patent license zerit yale university pursuant pays royalty based product sales japan company exclusive license zerit yamasa corporation pursuant pays royalty based net sales japan use patent expires united states june however pediatric extension earned thus exclusivity expected expire december patent series expires eu patent applications pending denmark finland japan december coumadin warfarin sodium cardiovascular product oral anticoagulant used predominantly patients atrial fibrillation deep venous thrombosispulmonary embolism warfarin acquired part dupont pharmaceuticals acquisition completed october market exclusivity expired united states basic patent protection regulatory data protection expired bms acquired coumadin company obtains bulk requirements warfarin third party produces majority finished goods facilities abilify aripiprazole neuroscience product atypical antipsychotic agent patients schizophrenia abilify introduced united states november companys partner otsuka pharmaceutical co ltd otsuka received approval supplemental new drug application snda aripiprazole maintaining stability patients schizophrenia announced submitted snda abilify treatment acute mania patients bipolar disorder fda otsuka holds new drug application nda aripiprazole united states marketing authorization application maa eu united states germany spain france company receives fee approximately net sales rest eu company purchases finished product approximately net sales books sales aripiprazole copromoted united states company otsuka bmss rights commercialize aripiprazole united states terminate thereafter otsuka sole right commercialize aripiprazole united states company also right copromote abilify several european countries united kingdom france germany spain act exclusive distributor product rest eu marketing approval received european authorities february otsuka received recommendation marketing approval abilify eu committee proprietary medicinal products expert advisory body european commission marketing authorization granted eu european commission company exclusive licensee product rest world excluding japan certain countries information companys arrangement otsuka see strategic alliances item financial statementsnote alliances investments basic us composition matter patent expires may extended pending supplemental protection extensions granted composition matter patent austria belgium finland greece ireland luxembourg portugal eu member states composition matter patent expires may extended pending supplemental protection certificates granted otsuka supplies bulk requirements aripiprazole otsuka bristolmyers squibb produce finished product facilities videxvidex ec didanosine virology product antiretroviral drug used treatment adult pediatric patients hivaids didanosine marketed company three different formulations first use oral solution second reduced mass tablet third enteric coated capsule formulation videx ec company license us governments patent series claims method using didanosine treat hiv patent series covers approved use three aforementioned formulations companys license became non exclusive october companys license use patent nonexclusive another company could potentially obtain license us government seek marketing approval us governments method use patent expires united states includes earned pediatric extension japan europe us government granted use patent austria belgium france germany italy luxembourg netherlands sweden united kingdom patent pending ireland expiration use patent eu occurs countrybycountry basis method use patent obtained us government denmark finland greece portugal spain videx reduced mass formulation company patents covering reduced mass formulation videx united states eu japan expire another company may attempt develop reduced mass formulation didanosine infringe patents videx ec enteric coated capsule company also pending patent applications cover videx ec formulation united states eu japan patents issue expiration another company may attempt develop enteric coated capsule formulation didanosine infringe pending patent applications us data exclusivity videx ec expires may japanese data exclusivity videx ec expires march company obtains materials necessary bulk manufacture didanosine third party produces finished product facilities tequin gatifloxacin infectious disease product broadspectrum methoxy fluoroquinolone antibiotic indicated treatment respiratory tract infections adults years older acute bacterial exacerbation chronic bronchitis acute sinusitis communityacquired pneumonia caused indicated susceptible strains grampositive gramnegative bacteria gatifloxacin licensed kyorin pharmaceuticals co ltd company purchases bulk gatifloxacin inclusive royalty based percentage net sales basic us patent expires however expected patent eligible statutory patent term extension patent term extension granted compensate patent holders portion patent life lost regulatory approval process gatifloxacin manufactured third party serzone nefazodone hydrochloride neuroscience product antidepressant treatment serzone subject pending product liability litigation plaintiffs allege company knew known certain risks associated product failed adequately warn physicians users risks discussion litigation see item financial statementsnote legal proceedings contingencies nefazodone developed internally basic patent expired united states september serzone longer marketed europe canada australia asia reyataz atazanavir sulfate virology product protease inhibitor treatment hivaids reyataz launched united states july company developed atazanavir worldwide license novartis pays royalty based percentage net sales basic composition matter patent expires united states atazanavir received marketing approval european authorities many current eu member states applications basic composition matter patent still pending issued patents expire japan basic composition matter patent expires buspar buspirone hydrochloride neuroscience product antianxiety agent persistent anxiety without accompanying depressive symptoms information regarding recently settled litigation involving buspar see item financial statements note legal proceedings contingencies buspirone developed internally us anxiolytic use patent expired although final marketing approval generic buspirone occur march patents outside united states expired erbitux cetuximab biologics product igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux designed bind internalize egfr prevent natural ligands called growth factors binding receptor activating signaling tumor erbitux approved fda february treatment combination irinotecan patients egfrexpressing metastatic colorectal cancer failed irinotecanbased regimen monotherapy patients intolerant irinotecan eribtux also studied earlier stages colorectal cancer well types cancer frequently express egf receptor including lung pancreatic ovarian head neck cancers erbitux marketed north america bristolmyers squibb distribution copromotion agreement imclone accordance agreement company paid imclone million march milestone payment approval erbitux fda company imclone share distribution rights erbitux merck kgaa japan description companys alliance imclone see strategic alliances item financial statementsnote alliances investments description companys supply agreement imclone see manufacturing quality assurance composition matter patent specifically claims erbitux erbitux approved monotherapy use patent use erbitux combination antineoplastic agent also approved fda combination use claimed granted us patent expires information biologics patents see intellectual property product exclusivity inventorship use patent challenged three scientists weizmann institute claim named coinventors information litigation see item financial statementsnote legal proceedings contingencies european equivalent use patent opposed addition pharmaceutical products discussed companys pharmaceuticals segment also includes companys wholly owned upsa business europe upsa brand acetaminophen efferalgan marketed pain relief across continent company also markets aspirine upsa dafalgan fervex europe overseas markets strategic alliances company enters strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties alliances take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances reduce risk research development expenses lead revenuegenerating products however gross margins alliance products generally lower sometimes substantially gross margins companys products profits alliance products shared companys alliance partners assurance new alliances formed company actively pursues arrangements views alliances important complement discovery development activities companys significant current alliances sanofi plavix avapro otsuka abilify imclone erbitux sankyo pravachol additionally company licensing arrangements rct paraplatin yale zerit us government videx novartis reyataz kyorin tequin sanofi company entered codevelopment commercialization agreement subsequently restructured sanofi two products avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy copromoted certain countries eu trade name aprovel comarketed certain countries eu company tradename karvea plavix clopidogrel platelet aggregation inhibitor copromoted certain countries eu tradename plavix comarketed certain countries eu company tradename iscover worldwide alliance operates framework two geographic territories one americas australia europe asia two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries country level agreements either copromote comarket place fourth quarter company sanofi modified commercialization arrangement irbesartan united states form copromotion joint venture part company contributed irbesartan intellectual property sanofi agreed pay company total million million company acts operating partner territory covering americas principally united states canada puerto rico latin american countries australia owns majority controlling interest territory company consolidates country partnership results territory records sanofis share results minority interest expense net taxes million million million company recorded sales territory comarketing countries germany italy spain greece million million million sanofi acts operating partner territory covering europe asia owns majority controlling interest territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million discussion matter see item financial statementsnote alliances investments otsuka company entered worldwide commercialization agreement otsuka codevelop commercialize abilify aripiprazole treatment schizophrenia total milestone payments made otsuka december million expensed company began copromoting product otsuka united states puerto rico november company also right copromote product several european countries marketing approval received european authorities company records alliance revenue share net sales copromotion countries records expenses related product company also exclusive right sell abilify number countries europe latin america asia countries sales commence company record net sales related cost sales company recorded revenue abilify million million discussion matter see item financial statementsnote alliances investments imclone november company purchased million shares imclone per share million represented approximately imclone shares outstanding prior companys commencement public tender offer imclone shares imclone biopharmaceutical company focused developing targeted cancer treatments include growth factor blockers cancer vaccines antiangiogenesis therapeutics equity investment imclone part strategic agreement company imclone also included arrangement codevelop copromote cancer drug erbitux series payments originally totaling billion company paid imclone milestone payment million march agreement imclone revised reduce total payments million billion revised agreement company paid imclone million march million march accordance agreement company paid imclone march million milestone payment approval erbitux fda payments capitalized amortized cost products sold remaining term agreement agreement imclone receive distribution fee based flat rate product revenues north america company purchase commercial requirements bulk erbitux imclone price equal manufacturing cost plus discussion matter see item financial statementsnote alliances investments company entered following significant alliances products clinical development corgentech october company corgentech inc biotechnology company entered agreement jointly develop commercialize corgentechs ef decoy edifoligide novel treatment prevention vein graft failure following coronary artery bypass graft peripheral artery bypass graft surgery product currently phase iii clinical trials fda granted fast track status indications company made expensed initial payment million october potential additional million clinical regulatory milestone payments time arrangements profit sharing flamel technologies sa august company entered exclusive license agreement flamel technologies sa develop market basulin first controlled release unmodified human insulin developed oncedaily injection patients type type diabetes basulin entered phase ii clinical development agreement company lead assume cost future development manufacturing efforts basulin exclusive worldwide rights product company paid expensed million october potential additional million clinical regulatory milestone payments time royalty payments product sales information alliances relating drug discovery see research development oncology therapeutics network segment otn leading specialty distributor oncology drugs supportive care products related supplies officebased oncologists united states wholesale market cancer pharmaceuticals united states seen shift administration chemotherapy almost exclusively hospital setting increased administration chemotherapy physicians offices outside hospital hospitalbased oncologists typically served drug wholesalers provide daily deliveries large quantities pharmaceutical products including oncology drugs related supplies hospital pharmacies hospitalbased oncologists rely hospital pharmacies order receive inventory drugs well maintain clinical drug information officebased oncologists lacking hospital pharmacy related services support generally face significant administrative burdens ordering stocking paying oncology drugs related supplies otns objective address cost containment needs reduce administrative burdens officebased oncologists attempting serve convenient costeffective single source supply oncology drugs related supplies reduce inventory associated carrying costs increase productivity oncology office provide reliable customeroriented service otn contracts individual healthcare providers well certain professional organizations negotiate discounts terms behalf member healthcare providers otn provides full range oncology products supplies variety manufacturers eliminating need customers interact multiple suppliers otns product catalog line items manufacturers however characteristic us market oncology pharmaceuticals small number products account majority otns sales otn sales accounted companys net sales companys net sales companys net sales dollar volume products shipped otn million compared million million sales could negatively affected new medicare legislation could impact oncologists treatment patterns reimbursement levels reduced discussion new medicare legislation see government regulation price constraints nutritionals segment nutritionals segment mead johnson manufactures markets distributes sells infant formulas nutritional products including entire line enfamil products company commenced sales enfamil lipil first infant formula united states contain nutrients dha docosahexaenoic acid ara arachidonic acid company obtains nutrients sole provider licensing supply arrangement also naturally found breast milk dha ara believed support infant brain eye development companys nutritionals products generally sold wholesalers retailers promoted primarily healthcare professionals company also promotes nutritionals products directly consumers worldwide advertising company manufactures products united states seven foreign countries nutritionals sales accounted companys sales domestic nutritionals sales accounted total nutritionals sales total nutritionals sales total nutritionals sales international nutritionals sales accounted total nutritionals sales total nutritionals sales total nutritionals sales approximately onehalf us sales infant formula subject rebates issued women infants children wic program sales subject wic rebates much lower margins nonwic sales net sales selected products product categories nutritionals segment follows restated restated dollars millions enfamil enfalac nutramigen childrens nutritional december part strategy focus infant childrens nutrition mead johnson agreed sell adult nutritional business novartis nutrition corporation business unit novartis ag mead johnson adult nutritional brands involved sale include boost complete oral nutritional beverage isocal isotonic tubefeeding formula ultracal general tubefeeding formula adult nutritional products recorded sales million terms agreement mead johnson sold novartis finished goods inventory brands trademarks patents intellectual property rights mead johnson global adult medical nutrition business million including million contingent product conversion million upfront payment supply agreement mead johnson continue manufacture supply majority sold products transaction closed february pretax gain approximately million expected recorded first quarter healthcare segment healthcare segment consists convatec medical imaging consumer medicines north america japan healthcare sales accounted companys sales companys sales companys sales domestic healthcare sales accounted total healthcare sales total healthcare sales total healthcare sales international healthcare sales accounted total healthcare sales total healthcare sales total healthcare sales convatec convatec manufactures distributes sells ostomy modern wound skin care products principal brands convatec include natura surfit esteem aquacel duoderm products marketed worldwide primarily hospitals medical profession medical suppliers company mainly relies internal sales force sales made various distributors around world company manufactures products united states united kingdom convatec sales accounted approximately companys sales domestic convatec sales accounted total convatec sales total convatec sales international convatec sales accounted total convatec sales total convatec sales company announced january agreed acquire acordis speciality fibres acordis privately held company based united kingdom licenses patent rights supplies materials convatec wound therapeutics line transaction subject regulatory approval received transaction completed company expects record inprocess research development charge million medical imaging medical imaging manufactures distributes sells cardiovascular imaging products including radiopharmaceuticals ultrasound agents principal brands medical imaging include cardiolite definity products marketed internal sales force sold worldwide primarily radiopharmacies hospitals clinics medical profession using small concentrated network radiopharmacies distribution connection companys international business medical imaging owns certain radiopharmacies outside united states cardiolite covered series patents claim components patent coverage differs somewhat countrybycountry basis united states patents expire december companys currently expected year basic exclusivity loss eu patents expire december japan patents expire august company manufactures products united states puerto rico medical imaging purchased part dupont pharmaceuticals acquisition closed october medical imaging sales accounted companys sales companys sales companys sales domestic medical imaging sales accounted total medical imaging sales total medical imaging sales total medical imaging sales international medical imaging sales accounted total medical imaging sales total medical imaging sales total medical imaging sales january company entered new license supply agreement cardinal health nuclear pharmacy services provides cardinal right sell cardiolite licensed pharmacy locations consumer medicines consumer medicines manufactures distributes sells overthecounter health care products principal consumer health care brands include excedrin brand products headache relief bufferin analgesics comtrex cold cough flu keri line moisturizers addition company began marketing choicedm line diabetic care products august products generally sold retailers promoted primarily consumers united states japan advertising products manufactured united states puerto rico japan consumer medicines sales accounted companys sales north american consumer medicines sales accounted consumer medicines sales consumer medicines sales consumer medicines sales consumer medicines sales japan accounted consumer medicines sales consumer medicines sales sources availability raw materials general bristolmyers squibb purchases raw materials open market substantially materials obtainable number sources loss one source supply would likely material adverse effect company discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance company seeks design operate manufacturing facilities maintain inventory way allow meet expected product demand maintaining flexibility reallocate manufacturing capacity improve efficiency respond changes supply demand pharmaceutical production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals discussion regulatory impact companys manufacturing see government regulation price constraints pharmaceutical manufacturing facilities require significant ongoing capital investment maintenance comply increasing regulatory requirements addition company adds product line realigns focus company expects close partially close modify many existing facilities devote substantial resources excess historical levels convert facilities meet heightened processing standards may required sterile newly introduced products particular biologics biologics manufacturing involves complex processes traditional pharmaceutical operations although company capacity manufacture biologics clinical trials commercial launch capacity manufacture larger commercial volumes products limited biologics become important companys product portfolio company may continue make arrangements thirdparty manufacturers may make substantial investments facilities increase maintain capacity produce biologics commercial scale company relies third parties manufacture supply active ingredients necessary manufacture certain products including pravachol plavix abilify coumadin paraplatin sustiva taxol tequin videxvidex ec maintain stable supply products company takes variety actions designed ensure adequate safety stock ingredients held thirdparty supplier bristolmyers squibb companys manufacturing operations interrupted additional protection cases company takes steps maintain approved backup source available company relies imclone supply erbitux cetuximab bulk requirements commercial use north america japan imclone currently seeking companys support fda approval manufacture erbitux imclones manufacturing facility somerville new jersey imclone contracted lonza biologics plc lonza act manufacturer cetuximab commercial launch cardinal health inc cardinal provide finishing assurance imclone granted regulatory approval manufacture erbitux approval occur supply cetuximab obtained lonza exhausted company also expects rely lonza manufacture abatacept leay commercial scale products commercialized abatacept leay investigational biologics compounds late stage development company made filings fda seeking approval lonza manufacture company market sell products assurance regulatory approval either products obtained however company entered agreement lonza reserve portion lonzas biologics manufacturing capacity companys future requirements products regulatory approval obtained terms agreement company minimum purchase requirements obligated pay lonza onetime termination fee products obtain regulatory approval additional information abatacept leay see research development company thirdparty manufacturer company relies existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet heightened processing requirements biologics companys business performance prospects could negatively impacted additionally company thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons company could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain companys pharmaceuticals certain circumstances company entered agreements company agreed supply products third parties addition liabilities could arise companys failure supply products agreements arrangements could require company invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products companys success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts companys operations including research development purchasing facilities planning manufacturing distribution company maintains qualityassurance procedures relating quality integrity scientific information production processes control production processes involves rigid specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling company performs tests various stages production processes final product assure product meets regulatory requirements companys standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used company subsidiaries thirdparty suppliers intellectual property product exclusivity company owns licensed number patents united states foreign countries primarily covering pharmaceutical products company also developed many brand names trademarks products areas company considers overall protection patent trademark license intellectual property rights material value acts protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity market exclusivity expires generic versions product approved marketed often substantial rapid declines products sales rate decline varies country therapeutic category discussion generic versions product impact products sales see generic competition products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example united states eu japan provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy regulatory intellectual property rights also available certain markets incentives research new indications orphan drugs medicines useful treating pediatric patients regulatory intellectual property rights independent patent rights company may possess particularly important drug lacks broad patent protection however regulatory forms exclusivity prevent competitor gaining regulatory approval basis competitors safety efficacy data drug even drug identical marketed innovator company assesses likely market exclusivity period products casebycase basis possible predict length market exclusivity companys products certainty complex interaction patent regulatory forms exclusivity inherent uncertainties enforceability certain intellectual property rights assurance particular product enjoy market exclusivity full period time company currently anticipates company expects continued exclusivity challenges next several years discussion exclusivity challenges see pharmaceuticals segment item managements discussion analysis financial condition results operationsoutlook addition patents regulatory forms exclusivity company also holds intellectual property form trademarks products excedrin enfamil theragran keri bufferin trademarks effect market exclusivity product considered marketing value worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely specific aspects law governing market exclusivity pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant company sales united states company seeking market innovative pharmaceutical united states must file complete set safety efficacy data fda type application filed depends whether drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company files nda medicine biological product biologics license application filed type application filed affects regulatory exclusivity rights competitor seeking launch generic substitute chemical innovative drug united states must file abbreviated new drug application anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda medicines approved nda receive several types regulatory data protection innovative chemical pharmaceutical also known new chemical entity entitled five years regulatory data protection anda filed fda innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation new indication basis new clinical trials receives three years data protection finally nda designated orphan drug drug gains indication treatment condition occurs rarely united states receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use significant portion patent life lost time takes obtain regulatory approval innovator extend one patent compensate innovator lost patent term least part specifically innovator may identify one patent claims product approved method use depending number factors may extend expiration patent two limits extensions first maximum patent extended years second extension cause patent effect years date nda approval company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity sixmonth period extends forms exclusivity patent regulatory listed fda time studies completed submitted fda currently generic versions biological products approved us law however fda taking steps toward allowing generic versions biologics laws could change near future competitors seeking approval biological products must file safety efficacy data beyond minimum period regulatory exclusivity provided us law many innovative drugs also covered patents held nda sponsor innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must choose whether file suit generic manufacturer protect patents one ndalisted patents successfully challenged innovator chooses sue first filer paragraph iv certification may entitled day period market exclusivity generic manufacturers time time andas including paragraph iv certifications filed respect certain companys products company evaluates andas casebycase basis warranted files suit generic manufacturer protect patent rights several recent developments united states increased likelihood generic challenges innovators intellectual property thus increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products discussion one litigation related patent challenges generic companies see item financial statementsnote legal proceedings contingenciesplavix litigation reflection statutory incentive challenge patentssix months semiexclusivity certain situationsas described second new statutory regulatory provisions united states limit ability innovator company prevent generic drugs approved launched patent litigation ongoing third fda actively considering abbreviated regulatory approval processes drugs similar generic copies innovative drugs result developments possible predict length market exclusivity particular company product certainty based solely expiration relevant patents current forms regulatory exclusivity information new legislation see government regulation price constraints european union eu innovative pharmaceuticals entitled ten years regulatory data protection marketing approval obtained via centralized procedure consequently regardless whether innovative medicine covered patents generic copies relying innovators data usually approved minimum ten years approval innovative pharmaceuticals gain marketing approval using noncentralized mutual recognition procedure period six ten years depending individual eu member state however regardless regulatory exclusivity competitors may obtain approval identical product basis safety efficacy data time information regarding regulation pharmaceutical products eu see government regulation price constraints patents pharmaceutical products generally enforceable eu however contrast united states patents listed regulatory authorities generic copies approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant united states patents eu may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis general eu law treats chemically synthesized drugs biologically derived drugs respect intellectual property market exclusivity japan japan medicines new chemical entities entitled six years protection approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data protection patent expirations united states patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemically synthesized biologically derived drugs respect intellectual property market exclusivity rest world countries outside united states eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either united states eg canada eu eg switzerland among less developed countries adopted patent laws andor regulatory exclusivity laws others less developed nations formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto obligations long process assurance outcome thus assessing likely future market exclusivity companys innovative drugs less developed countries company takes account formal legal rights political factors well marketing distribution customers companys pharmaceuticals segment convatec medical imaging businesses company promotes products medical journals directly health care providers doctors nurse practitioners physician assistants pharmacists hospitals pharmacy benefit managers pbms managed care organizations mcos government agencies company also markets directly consumers united states directtoconsumer print radio television advertising addition company sponsors general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceuticals see government regulation price constraints companys sales marketing organizations company explains approved uses advantages products medical professionals company works gain access health authority pbm mco formularies lists recommended approved medicines products reimbursement lists demonstrating qualities treatment benefits products company also works mcos pbms assist disease management patient education tools benefit patients improving medical treatment routines marketing prescription pharmaceuticals limited approved uses particular product company continues develop information products provides information response inquiries doctors medical professionals drugs must complete clinical trials required regulatory authorities show safe effective treating one medical problems manufacturer may choose however undertake additional studies including comparative clinical trials competitive products demonstrate additional advantages compound studies costly take years complete results uncertain balancing considerations makes difficult decide whether undertake additional studies successful studies major impact approved marketing claims strategies companys operations include several pharmaceutical sales organizations sales organization markets distinct group products typically based particular therapeutic areas physician groups sales organizations often focus selling new products introduced marketing physicians increasingly targeted specialists high value primary care physicians companys prescription pharmaceutical products sold principally wholesalers company also sells directly retailers hospitals clinics government agencies pharmacies sales three pharmaceutical wholesalers united states mckesson corporation mckesson cardinal amerisourcebergen corporation amerisourcebergen accounted approximately respectively companys total net sales sales amerisourcebergen mckesson accounted approximately companys total net sales sales cardinal accounted companys total net sales sales amerisourcebergen cardinal mckesson accounted approximately companys total net sales sales us wholesalers concentrated pharmaceuticals segment apart instances none companys business segments dependent one customer group related customers april company disclosed substantial buildup wholesaler inventories us pharmaceuticals business developed subsequently undertook plan workdown orderly fashion wholesaler inventory levels company took steps intended moderate investment buying us pharmaceutical wholesalers result sales fluctuations unrelated consumer demand company entered new inventory management agreements imas amerisourcebergen cardinal mckesson wholesalers agreements terms years cancelable either parties year imas generally establish limits inventory levels bms pharmaceutical products held wholesalers permit limited buyins bms pharmaceutical products wholesalers price increases preprice increase prices require wholesalers provide company data association wholesalers sales inventory levels bms pharmaceutical products otn acts bmss exclusive sales distributor bms oncology products officebased oncologists otn believes extensive customer base coupled overall competitive pricing customer service make attractive drug manufacturers wish serve officebased oncologist community focused distribution channel otn provides services manufacturers include support product launch customer specific marketing programs data services rapid market research company entered agreement mckesson mckesson acts exclusive distributor pharmaceutical products otn terms agreement mckesson provides warehousing packing shipping purchasing inventory management administrative support services bms products pharmaceutical products marketed promoted sold otn otn recognizes revenue terms mckesson agreement using consignment model described item financial statementsnote accounting policies revenue recognition company exclusive distributor erbitux north america otn terms agreement mckesson mckesson provides otn warehousing packing shipping filling orders erbitux maintain integrity product special storage conditions handling required accordingly sales erbitux including purchase requests wholesalers processed otn mckesson ship erbitux endusers product intermediaries hold later sales information sales marketing consumer medicines nutritionals see nutritionals segment healthcare segmentconsumer medicines competition markets bristolmyers squibb competes generally broadbased highly competitive principal means competition vary among product categories business groups companys pharmaceuticals segment competes worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated cost effectiveness marketing effectiveness product labeling service research development new products processes sales companys products impacted new studies indicate competitors product greater efficacy treating disease particular form disease one companys products companys sales also impacted additional labeling requirements better tolerability safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages companys products subject progressive price reductions decreased volume sales example growing market statins reduce cholesterol pravachol companys largest product net sales competes established brands new entrants several worlds largest pharmaceutical companies product beginning lose exclusivity markets loss us exclusivity expected rate decline market share could accelerated recent clinical studies successfully compete business managed care pharmacy benefits management organizations company must often demonstrate products offer medical benefits also cost advantages compared forms care new products company introduces must compete products already market products later developed competitors manufacturers generic pharmaceuticals typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product certain countries outside united states patent protection weak nonexistent company must compete generic versions shortly launches innovative product many companies large small manufacture sell one products similar marketed companys nutritionals healthcare segments sources competitive advantage include product quality efficacy brand identity advertising promotion product innovation broad distribution capabilities customer satisfaction price significant expenditures advertising promotion marketing generally required achieve consumer trade acceptance products company believes longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment assurance companys research development efforts result commercially successful products products processes become outmoded time time result products processes developed competitors managed care organizations growth mcos united states major factor competitive makeup healthcare marketplace half us population participates version managed care size patient population covered mcos marketing prescription drugs pbms serve many organizations become important companys business mcos include medical insurance companies medical plan administrators healthmaintenance organizations alliances hospitals physicians physician organizations organizations consolidating fewer even larger entities enhancing purchasing strength importance company major objective mcos contain possible reduce health care expenditures typically use formularies volume purchases longterm contracts negotiate discounts pharmaceutical providers mcos pbms typically develop formularies reduce cost medications formularies based prices therapeutic benefits available products due generally lower cost generic medicines often favored breadth products covered formularies vary considerably one mco another many formularies include alternative competitive products treatment particular medical problems mcos use variety means encourage patients use products listed formularies exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price company generally although universally successful major products included mco formularies generic competition one biggest competitive challenges company faces united states internationally generic pharmaceutical manufacturers upon expiration loss market exclusivity product company lose major portion sales product short period time united states fda approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allows generic manufacturers rely safety efficacy pioneer product therefore generic competitors operate without companys large research development expenses costs conveying medical information product medical community information market exclusivity see intellectual property product exclusivity rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries also declines developed countries tend rapid less developed countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture noted mcos focus primarily immediate cost drugs often favor generics brandname drugs many governments also encourage use generics alternatives brandname drugs health care programs laws united states generally allow cases require pharmacists substitute generic drugs rated government procedures therapeutically equivalent brandname drug substitution must made unless prescribing physician expressly forbids laws policies provide added incentive generic manufacturers seek marketing approval automatic substitution removes need generic manufacturers incur sales marketing costs innovators must incur research development company invests heavily research development believes critical longterm competitiveness pharmaceutical research development carried bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities united states belgium canada france united kingdom management continues emphasize leadership innovation productivity quality strategies success pharmaceutical research institute company spent million million million company sponsored research development activities company sponsored pharmaceutical research development spending including certain payments thirdparty collaborations contracts percentage pharmaceutical sales compared end company employed approximately people research development throughout company including pharmaceutical research institute including substantial number physicians scientists holding graduate postgraduate degrees higher skilled technical personnel company concentrates pharmaceutical research development efforts following ten disease areas affective psychiatric disorders alzheimersdementia atherosclerosisthrombosis diabetes hepatitis hivaids obesity oncology rheumatoid arthritis related diseases solid organ transplant however company continues analyze selectively pursue promising leads therapeutic areas addition discovering developing new chemical compounds company looks ways expand value existing products new uses formulations provide additional benefits patients supplement companys internal efforts company collaborates independent research organizations including educational institutions researchbased pharmaceutical biotechnology companies company contracts others performance research facilities company uses services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products company actively seeks investments external research technologies hold promise complement strengthen research efforts investments take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures drug development timeconsuming expensive risky development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug may marketed united states recorded data preclinical clinical experience included nda biological product license application bpla fda required approval development certain products also subject government regulations covering safety efficacy united states many foreign countries assurance compound result particular program obtain regulatory approvals necessary marketed particular disease indication average one ten thousand chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine process discovery regulatory approval typically takes ten years longer drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval company believes investments research internally collaboration others rewarded number new pharmaceutical compounds indications stages development bristolmyers squibbs drug discovery program includes many alliances collaborative agreements agreements bring new products pipeline help company remain cutting edge technology search novel medicines example december company formed partnership lexicon genetics incorporated lexicon develop drugs field depression anxiety schizophrenia pain alzheimers disease terms agreement lexicon contribute products drug discovery programs alliance give company exclusive access discoveries neurological sciences field lexicon gene analysis program known genome lexicon received upfront payment million bristolmyers squibb fourth quarter expensed company receive minimum million research funding first three years agreement bristolmyers squibb option extend part agreement another two years return providing additional research funding million lexicon receive funding novel drug developed alliance earn royalties sales drugs commercialized bristolmyers squibb december company also announced extension expansion oncology research collaboration exelixis inc exelixis two companies continue identify validate molecular targets implicated genesis cancer original agreement established threeyear term july terms extended collaboration bms provided exelixis upfront payment million increased annual research funding milestone payments certain cancer targets arising collaboration exelixis bristolmyers squibb agreed extend collaboration december bristolmyers squibb right continue collaboration july goal extension increase total number degree validation cancer targets exelixis deliver company exelixis bristolmyers squibb maintain option obtain exclusive worldwide rights equal numbers validated targets arising collaboration listed several investigational compounds company later stages development compounds entering phase iib phase iii clinical trials whether investigational compounds ultimately becomes one companys marketed products depends results preclinical clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale company expects file fda approval abatacept entecavir muraglitazar early however noted assurance company seek regulatory approval compounds approval sought obtained stage development company determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted include potential term extensions abatacept ctlaig biological product developed internally currently phase iii clinical trials fusion protein novel immunosuppressive activity targeted initially rheumatoid arthritis company series patents covering ctlaig method use latest composition matter patents expires united states repligen corporation repligen patent claims use ctlaig treat specific autoimmune diseases including rheumatoid arthritis litigation concerning inventorship ctlaig also ongoing information litigation see item financial statementsnote legal proceedings contingencies entecavir entecavir developed internally currently phase iii clinical trials potent selective inhibitor hepatitis b virus company composition matter patent expires united states ef decoy edifoligide developed jointly corgentech entering phase iii clinical trials novel treatment prevention vein graft failure following coronary artery bypass graft peripheral artery bypass graft surgery company license corgentechs numerous issued pending patent applications cover product two patents issued united states expire ixabepilone ixabepilone epothilone developed internally currently phase iii clinical trials novel tubulin inhibitor multiple tumor types company composition matter patent united states expire muraglitazar muraglitazar developed internally currently phase iii clinical trials dual ppar agonist treatment type diabetes metabolic disorders company compositionofmatter patent expires united states leay leay biological product developed internally currently phase iib clinical trials fusion protein novel immunosuppressive activity targeted solid organ transplant company pending patent applications united states eu japan covering leay razaxaban razaxaban currently phase iib clinical trials factor xa inhibitor prevention deep vein thrombosis razaxaban acquired part companys acquisition dupont pharmaceuticals developed internally company composition matter patent expires united states companys competitors also devote substantial funds resources research development addition consolidation occurred companys industry created companies substantial research development resources extent companys competitors successful research could result erosion sales products unanticipated product obsolescence government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion companys products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition companys operations subject complex federal state local foreign environmental occupational safety laws regulations company anticipates laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense significant capital investment particular importance fda united states jurisdiction virtually companys businesses imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance companys pharmaceutical products fda also regulates companys nutritionals healthcare products many cases fda requirements increased amount time money necessary develop new products bring market united states companys pharmaceutical products subject premarket approval requirements united sates new drugs approved subject fdc act related regulations biological drugs subject fdc act public health service act known phs act related regulations biological drugs licensed phs act fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production record keeping quality control ensure product meets applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy product occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed company could materially adversely affect business financial condition results operations marketing authorization companys products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act known pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel record keeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples diversions company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission ftc department justice department health human services united states company also licensed us drug enforcement agency procure produce controlled substances company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies various federal state agencies regulatory authority regarding manufacture storage transportation disposal many medical imaging products radioactive nature companys activities outside united states also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing companys products regulatory requirements vary country country eu two ways company obtain marketing authorization pharmaceutical product first route centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products product receives approval centralized procedure automatically receives approval every member state eu however company must obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure take months sometimes years obtain second route obtain marketing authorization eu mutual recognition procedure applications made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states set forth pricing reimbursement product continues subject member state law whether fda approval approval european medicines evaluation agency obtained product approval product comparable regulatory authorities countries outside united states eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required united states approval one country assure product approved another country markets outside united states company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted across theboard price cuts methods cost control exception germany united kingdom european country market pricing new medicines pricing freedom limited united kingdom operation profit control scheme germany operation reference price system companies also face significant delays market access new products two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within europe due different national pricing reimbursement laws leads significant parallel trade flows recent years congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others similar issues exist many foreign countries company business december new medicare legislation enacted provides outpatient prescription drug coverage senior citizens united states legislation interim drug discount card program scheduled begin june main drug benefit eligibility standalone drug plan scheduled begin new drug benefit administered regionally private insurance plans pharmacy benefit managers law allows medicare negotiate directly pharmaceutical companies regions without private drug benefit program legislation allows importation less expensive prescription drugs canada us health human services department certifies safety far done assurance certification requirement maintained future legislation certification continue withheld company predict potential impact legislation business clear law implemented regulators received consumers physicians impact negative companys us oncology business reimbursement levels reduced certain oncology products administered outpatient setting including paraplatin impact could also negative intermediate longer term companys us pharmaceutical business generally greater federal involvement budget constraints may increase likelihood pricing pressures controls future federal state governments also pursued direct methods reduce cost drugs pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense united states governmental costcontainment efforts extended federally funded special supplemental nutrition program wic states participate wic sought obtained rebates manufacturers infant formula whose products used program states conducted competitive bidding infant formula contracts require use specific infant formula products state wic program unless physician requests noncontract formula wic customer states participating wic required engage competitive bidding use another cost containment measure yields savings equal greater savings generated competitive bidding system mead johnson participates program approximately us sales subject rebates wic pending pharmaceutical legislation eu expected adopted year impact procedures authorization pharmaceutical products eu centralized mutual recognition procedures particular legislation contains new data protection provisions products regardless whether approved centralized nationalmutual recognition procedures subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities however generic company may commercialize product either ten eleven years elapsed initial marketing authorization granted innovator possible one year extension available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments transitional provision new data protection requirements expected provisions apply new innovator products approved new legislation japan recently adopted regulations filing new drugs effective july may streamline filing process international companies introducing new compounds japan allowing international clinical nonclinical data used filing process planned merger two japanese pharmaceutical regulatory offices may also lead gains efficiency timeliness drug registration japan however pricing policy pharmaceuticals japan remains challenging due biannual government mandated price reductions environmental regulation companys facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many companys operations permits subject modification renewal revocation issuing authorities corporate environment health safety group monitors operations around world providing company overview regulatory requirements overseeing implementation company standards compliance company also incurs operating capital costs matters ongoing basis company expended approximately million million capital environmental projects undertaken specifically meet environmental requirements respectively expects spend approximately million although company believes substantial compliance applicable environmental health safety requirements permits required operations company nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many companys current former facilities operation many years time company operators facilities generated used stored disposed substances wastes considered hazardous environmental laws result soil groundwater certain facilities may contaminated company may required make significant expenditures investigate control remediate contamination company also potentially responsible environmental conditions number waste disposal reprocessing facilities operated third parties currently company involved investigation remediation activities approximately sites named potentially responsible party prp us comprehensive environmental response compensation liability act cercla approximately sites cercla similar state statutes may impose liability entire cost investigation remediation contaminated sites party regardless fault ownership time disposal release generally multiple potentially responsible parties liability apportioned based nature amount hazardous substances disposed party site number financially viable parties based companys current estimates cleanup costs expected share financial responsibility company expect expenditures connection cercla remediation matters material expenditures could rise future substantial unknown contamination discovered one companys current former facilities prps fail participate costsharing site financial responsibility additional information matters see item financial statementsnote legal proceedings contingencies employees bristolmyers squibb employed approximately people december foreign operations company significant operations outside united states conducted companys subsidiaries distributors involve three business segmentspharmaceuticals nutritionals healthcareas companys us operations revenues operations outside united states billion accounted companys total revenues revenues exceeded million six countries outside united states single country outside united states contributed companys total revenues geographic breakdown net sales yearend assets see table captioned geographic item financial statementsnote segment information international operations subject certain risks inherent conducting business abroad including currency fluctuations possible nationalization expropriation price exchange controls limitations foreign participation local enterprises restrictive governmental actions companys international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase reduce reported dollar value companys net assets results operations change foreign exchange rates net favorable impact revenues company predict certainty future changes foreign exchange rates effect company attempts mitigate impact operational means using various financial instruments see discussion item financial statementsnote financial instruments december approximately billion cash cash equivalents marketable securities held companys foreign subsidiaries company expect repatriate foreseeable future company expects cash generated us operations together borrowings capital markets sufficiently cover cash needs working capital capital expenditures dividends us repatriation cash united states would require additional tax provisions reflected consolidated financial statements discussion matter see item managements discussion analysis financial condition results operationscritical accounting policiesincome taxes item properties bristolmyers squibbs world headquarters located park avenue new york new york leases approximately square feet floor space approximately square feet sublet others bristolmyers squibb manufactures products major worldwide locations aggregate floor space approximately square feet facilities owned bristolmyers squibb following table illustrates geographic location companys significant manufacturing facilities business segment total company pharmaceuticals nutritionals healthcare united states europe middle east africa western hemisphere pacific total portions facilities facilities owned leased bristolmyers squibb united states elsewhere used research administration storage distribution information companys facilities see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item submission matters vote security holders matters submitted vote security holders fourth quarter year ended december part ia executive officers registrant listed information executive officers company march executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti vice president general manager italy oncology europe division senior vice president president company international senior vice president general manager italy ceei european oncology member executive committee division company president europe present senior vice president president international harrison bains jr vice president treasurer corporate staff company vice president tax treasury vice president acting chief financial officer corporate staff company corporate staff present vice president tax treasury corporate staff company stephen e bear vice president strategic business development worldwide beauty carenutritionals senior vice president human resources medical devices corporate staff company corporate staff vice president marketing business development new york botanical member executive committee gardens nonprofit organization present senior vice president human resources corporate staff company andrew g bodnar md vice president strategic business development worldwide medicines group senior vice president strategy division company medical external affairs corporate staff vice president corporate development worldwide medicines group division member executive committee company vice president medical external affairs corporate staff company senior vice president medical external affairs corporate staff company present senior vice president strategy medical external affairs corporate staff company andrew r j bonfield deputy finance director smithkline beecham plc senior vice president chief chief financial officer smithkline beecham plc financial officer corporate staff executive director finance bg group plc member executive committee present senior vice president chief financial officer corporate staff company wendy l dixon phd vice president marketing merck co chief marketing officer president senior vice president merck co global marketing present chief marketing officer president global marketing worldwide medicines member executive committee pharmaceuticals group division company name current position age employment history past years peter r dolan senior vice president strategy organizational effectiveness corporate staff chairman board chief company executive officer president director company member executive committee present chairman board chief executive officer company donald j hayden senior vice president president worldwide medicines group division executive vice president president company americas executive vice president ebusiness strategy corporate staff company member executive committee executive vice president ebusiness strategy investor relations corporate intelligence corporate staff company executive vice president health care group executive vice president president north america medicines present executive vice president president americas anthony c hooper vice president general manager northern europe international medicines president us pharmaceuticals president asiapacific middle east southern africa international medicines member executive committee president intercontinental international medicines president europe africa worldwide medicines group present president us pharmaceuticals worldwide medicines group tamar howson senior vice president director business development smithkline beecham senior vice president corporate corporation development corporate staff biotechnology consultant chief executive officers business executives member executive committee present senior vice president corporate development corporate staff company paul w karr deputy controller ge capital services vice president financial controller senior vice president chief accounting officer ge capital markets services corporate staff present vice president financial controller corporate staff company sandra leung associate counsel corporate staff company vice president corporate counsel corporate staff company secretary corporate staff corporate secretary corporate staff company present vice president corporate secretary corporate staff company name current position age employment history past years john l mcgoldrick general counsel senior vice president corporate staff company executive vice president general president medical devices group division company counsel corporate staff executive vice president general counsel corporate staff company member executive committee president medical devices group division company present executive vice president general counsel corporate staff company james b palmer md frcp senior vice president director group medical regulatory product strategy chief scientific officer corporate staff glaxo wellcome research development president pharmaceutical research senior vice president new product development glaxosmith kline institute present chief scientific officer corporate staff company president member executive committee pharmaceutical research institute division company elliott sigal md phd vice president applied genomics pharmaceutical research institute division senior vice president global clinical company pharmaceutical development senior vice president early discovery applied technology pharmaceutical pharmaceutical research institute research institute division company member executive committee senior vice president drug discovery exploratory development pharmaceutical research institute division company present senior vice president global clinical pharmaceutical development pharmaceutical research institute division company john l skule presentsenior vice president corporate environmental affairs corporate staff senior vice president corporate company environmental affairs corporate staff member executive committee part ii item market registrants common stock related stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange pacific exchange inc symbols bmy bmypr quarterly summary high low market prices presented common high low high low first quarter second quarter third quarter fourth quarter preferred high low high low first quarter second quarter third quarter fourth quarter first second third quarters first quarter trades companys preferred stock preferred stock pays quarterly dividend per share holders common stock number record holders common stock december number record holders based upon actual number holders registered books bristolmyers squibb date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies voting securities principal holders reference made proxy statement filed march respect voting securities principal holders incorporated herein reference made part hereof response information required item dividends dividends declared per share common preferred first quarter second quarter third quarter fourth quarter december board directors company declared quarterly dividend per share common stock company paid february shareholders record january item selected financial data fiveyear financial summary set forth item revised reflect restatement discussion restatement see item financial statements note restatement previously issued financial statements years ended december fiveyear financial summary restated restated restated restated millions except per share data income statement data net sales earnings continuing operations minority interest income taxes earnings continuing operations earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded several items affected comparability results set forth table item managements discussion analysis financial condition results operationsearnings years discussion items see item managements discussion analysis financial condition results operationsnet sales item financial statementsnote alliances investments note restructuring items note acquisitions divestitures note discontinued operations restatement adjustments affecting years set forth following table includes discontinued operations years previously previously reported restated reported restated dollars millions net sales earnings continuing operations earnings continuing operations per common share basic diluted financial position data december total assets stockholders equity restatement adjustments affecting years adjustments respect net sales intercompany foreign exchange gains losses international pension employee benefit plan accruals income taxes restatement items described item financial statementsnote restatement previously issued financial statements item managements discussion analysis financial condition results operations managements discussion analysis financial condition results operations set forth item revised reflect restatement summary company reported annual global sales billion sales increased prior year level reflecting volume increases net price increases impact foreign exchange fluctuations us sales increased partly due impact sales workdown non consignment wholesaler inventory international sales increased including favorable foreign exchange impact company two product lines sales billion eachpravachol plavix pravachol sales grew including favorable foreign exchange impact billion plavix sales grew including favorable foreign exchange impact billion addition two products company product lines million annual sales including product lines million annual sales six annual sales excess million earnings continuing operations minority interest income taxes increased million million net earnings continuing operations million per share basic diluted basis respectively compared million per share basic diluted basis company expects exclusivity losses new product mix challenge margins company remains committed investing businesses maximize key growth drivers advance pipeline several items affected comparability results discussed earnings outlook december company held almost billion cash cash equivalents marketable securities approximately billion cash cash equivalents marketable securities held companys foreign subsidiaries company expect repatriate foreseeable future company expects cash generated us operations together borrowings capital markets sufficiently cover cash needs working capital capital expenditures dividends us repatriation united states would require additional tax provisions reflected consolidated financial statements discussion matter see critical accounting policiesincome taxes company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity additional discussion matter see item financial statementsnote legal proceedings contingencies longterm debt increased billion december billion december primarily due billion fixed rate notes billion floating rate convertible debentures issued august october respectively proceeds issuances used repay short term borrowings fund cash needs us operations cash provided operating activities billion working capital billion december company paid dividends approximately billion provided dividend yield consistent companys mission extend enhance human life developing highestquality products company invested billion research development growth research development dedicated pharmaceutical products including milestone payments licensing development programs billion percentage pharmaceutical sales compared compound annualized growth pharmaceutical research development spending past five years restatement previously issued financial statements company restating consolidated balance sheet december consolidated statements earnings cash flows comprehensive income retained earnings years ended december financial statements first second third quarters including comparable interim periods restatement restatement affects periods prior impact restatement prior periods reflected adjustment opening retained earnings january restatement reported annual report year ended december reported amendments quarterly reports form q quarterly periods ended march june september restatement corrects certain companys historical accounting policies conform us generally accepted accounting principles gaap ii corrects certain errors made application gaap late october company determined certain sales certain wholesalers us pharmaceuticals business accounted consignment sales accounting model accordingly determined restate sales earnings sales wholesalers following determination company also determined would correct certain historical accounting policies conform accounting gaap certain known errors made application gaap previously recorded case company believed amount error material companys consolidated financial statements addition part restatement process company investigated accounting practices certain areas involve significant judgments determined restate additional items respect company concluded errors made application gaap including certain revisions inappropriate accounting march company completed restatement financial statements items restated financial statements three years ended december including corresponding interim periods first second quarters including comparable prior interim periods restatement completing restatement company continued identify implement actions improve effectiveness disclosure controls procedures internal controls financial reporting connection effort company substantially strengthened organization personnel senior financial control functions ii adopted rigorous policies procedures respect balance sheet review process iii focused internal audit function financial reporting controls iv engaged consultant assist evaluation documentation certain financial reporting disclosure processes throughout company v engaged consultant assist comprehensive detailed review certain companys tax reporting accounting addition request companys audit committee companys independent auditors performed extensive procedures respect companys interim financial information based auditors assessment companys risk profile expanded scope amount field work performed certain areas connection audit company actions contributed significantly company identifying additional errors relating prior periods reflected restatement discussion individual restatement adjustments see item financial statementsnote restatement previously issued financial statements years ended december connection audits restatement companys consolidated financial statements year ended december companys independent auditors pricewaterhousecoopers llp pwc identified communicated company audit committee two material weaknesses defined standards established american institute certified public accountants relating companys accounting public financial reporting significant matters initial recording management review oversight certain accounting matters addition time pwc identified communicated company audit committee reportable condition defined standards established american institute certified public accountants relating companys internal controls financial reporting income taxes company dedicated substantial resources improving controls accounting financial disclosure reporting auditors identified material weaknesses connection audit financial statements addition company devoted substantial resources towards remedying reportable condition relation taxes company also retained consultant assist comprehensive detailed review certain aspects tax accounting reporting company examined financial reporting taxes significant jurisdiction company one subsidiaries subject tax result review number prior period errors identified reflected restatement addition company undertook review evaluate certain issues raised concerning manner company determined provision income taxes company determined prior certain inappropriate adjustments tax contingency reserves made improper purpose recording provision income taxes consistent companys projected effective tax rate addition may inappropriate adjustments company completed review able determine whether errors relating tax contingency reserves corrected restatement related inappropriate accounting connection audit companys consolidated financial statements year ended december pwc advised company audit committee reportable condition income tax accounting area remains company expects complete remediation reportable condition end throughout managements discussion analysis financial condition result operations referenced amounts prior periods prior period comparisons reflect balances amounts restated basis net sales sales billion increase prior year increase sales driven volume increased levels partly due impact sales workdown nonconsignment wholesaler inventory us sales increased million compared decrease million international sales increased million including favorable foreign exchange impact compared increase million significant foreign exchange impact general companys business seasonal information us pharmaceuticals prescriber demand reference made table within business segments pharmaceuticals section sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys primary care pharmaceutical products sales billion compared billion increase sales included approximately million million respectively sales related products acquired part dupont pharmaceuticals acquisition dupont pharmaceuticals completed october domestic sales decreased million international sales increased million foreign exchange significant impact composition net increase sales follows restated volume selling prices net foreign exchange increase sales significant portion companys us pharmaceuticals sales made wholesalers company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers including discounts buyins anticipation price increases extended payment terms certain us pharmaceuticals wholesalers generally offered toward end quarter incentive wholesalers purchase products amount sufficient meet companys quarterly sales projections established companys senior management timing companys recognition revenue sales wholesalers differs wholesaler period historically company recognized revenue sales upon shipment products customers gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments situations described utilizing consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue net discounts rebates estimated sales allowances accruals returns consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout fifo basis additional discussion companys revenue recognition policy see item financial statements note accounting policies restatement company restated previously issued financial statements period second quarter correct timing revenue recognition certain previously recognized us pharmaceuticals sales cardinal health inc cardinal mckesson corporation mckesson two largest wholesalers companys us pharmaceuticals business based application criteria recorded error time shipment accounted using consignment model december companys aggregate cost pharmaceutical products held cardinal mckesson accounted using consignment model accordingly reflected consignment inventory companys consolidated balance sheet approximately million million respectively approximately million million december respectively related oncology products sold oncology therapeutics network otn deferred revenue recorded gross invoice sales price related inventory pharmaceutical products accounted using consignment model approximately million million december respectively approximately million million december respectively related otn result restatement application consignment model approximately million sales excluding otn net discounts rebates adjustments reversed period approximately million million recognized respectively consigned inventory held cardinal mckesson worked significant portion workdown recognized first quarter corresponding effect earnings continuing operations minority interest income taxes increase million million respectively sales cardinal mckesson represented approximately us pharmaceuticals net sales respectively company estimates based data noted inventory pharmaceutical products held us pharmaceuticals wholesalers range approximately million excess approximately one month supply december estimate subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflect limitations company expects account certain pharmaceutical sales relating otn using consignment model agreement mckesson expires earnings earnings continuing operations minority interest income taxes increased million million increase primarily result sales increase specified charges million recorded litigation settlements asset impairments writeoffs process research development increase partially offset increased investment advertising promotion marketing selling administrative expenses earnings continuing operations increased million million basic diluted earnings per share continuing operations increased respectively respectively earnings continuing operations minority interest income taxes increased million million earnings continuing operations increased million million basic diluted earnings per share continuing operations increased respectively respectively net earnings margins continuing operations increased years ended december company recorded several items affected comparability results periods presented herein set forth following table discussion items see item financial statementsnote alliances investments note restructuring items note acquisitions divestitures note discontinued operations restated restated dollars millions acquired inprocess research development litigation charge net asset impairment charge investment imclone restructuring items gain sales businessesproduct lines income tax benefit items settlement prior year tax matters restructuring items consist following cost provision products restructuring year ended december sold rd total dollars millions upfront payments four licensing agreements accelerated depreciation assets termination benefits exit costs relocation expenses asset impairment charges retention benefits change estimates cost provision products restructuring year ended december sold rd total dollars millions termination benefits exit costs accelerated depreciation assets asset writedown impairment charges change estimates decrease cost provision net products restructuring year ended december sales sold total dollars millions downsized rationalized operations facilities abandonment nonstrategic pharmaceutical product lines change estimates gross margin percentages respectively gross margins negatively impacted due increased sales lowermargin products otn segment million accelerated depreciation charges million charge asset impairment restructuring expenses largely offset increased sales higher margin products pravachol lower gross margin compared principally due impact generic competition united states glucophage ir taxol buspar adverse change product mix due increased sales otn segment effective income tax rate earnings continuing operations minority interest income taxes compared increase effective tax rate effective tax rate primarily due decrease effective tax rate benefit operations ireland puerto rico switzerland treatment provisions certain litigation reserves nondeductible increase estimates contingent tax matters compared increase effective tax rate effective tax rate primarily due decrease effective tax rate benefit operations ireland puerto rico switzerland provision million valuation allowances comprised million related certain state foreign net deferred tax assets million related certain state foreign tax net operating loss tax credit carryforwards partially offset million net release tax contingency reserves related primarily settlement prior year tax matters determination company expected settlement ongoing tax litigation resolved company currently believes state net deferred tax assets state net operating loss tax credit carryforwards foreign net operating loss tax credit carryforwards valuation allowances provided likely realized future lower effective income tax rate results primarily lower pretax income united states due writeoff acquired process research development well proportionately greater tax benefits income earned lower tax rate jurisdictions ireland puerto rico switzerland expenses total costs expenses percentage sales compared cost products sold percentage sales increased last three years compared principally due increased sales lowermargin products otn largely offset increased sales higher margin products pravachol cost products sold includes million accelerated depreciation assets manufacturing facilities north america expected closed end million charge asset impairment restructuring expenses cost products sold included million reversal prior period reserves inventory writeoffs related cancelled actions included million restructuring expenses marketing selling administrative expenses percentage sales decreased marketing selling administrative expenses increased million million primarily due increased sales support abilify avaproavalide higher pension costs higher charges related system infrastructure higher insurance premiums unfavorable foreign exchange impact principally related euro marketing selling administrative expenses percentage sales increased million million slight increase mainly due higher sales force expenses result addition medical imaging business acquired october advertising promotion expenses increased million million primarily result promotional support abilify reyataz launches plavix united states additional support inline products unfavorable foreign exchange impact europe advertising promotion expenses decreased million million primarily result reduced spending metformin franchise vaniqa partially offset abilify product launch expenses increased support plavix avaproavalide united states percentage sales advertising promotion expenses increased companys investment research development totaled million increase increase percentage sales decreased compared research development costs included million charges related upfront payments licensing agreements million accelerated depreciation research facilities research development spending dedicated pharmaceutical products decreased pharmaceuticals sales compared respectively company focusing research development activities fully realize value research development pipeline new priorities include rebalancing drug discovery development increase support companys full latestage development pipeline closing unnecessary facilities also include devoting greater resources ensuring successful nearterm product launches increasing companys efforts inlicensing opportunities charges related acquired inprocess research development million primarily related milestone payments imclone systems incorporated imclone erbitux million milestone payment imclone million expensed acquired inprocess research development first quarter remaining million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquired inprocess research development charge million including million related dupont pharmaceuticals acquisition million attributable imclone equity investment addition acquired inprocess research development includes charges million million respectively licensing payments related products yet approved marketing restructuring programs implemented downsize realign streamline operations order increase productivity reduce operating expenses rationalize companys manufacturing network research facilities administrative functions actions restructuring program expected complete actions restructuring programs substantially complete december result actions company expects future annual benefit earnings continuing operations minority interest income taxes approximately million million million programs respectively additional information restructuring see item financial statementsnote restructuring items litigation charges net settlement income million compared million million fourth quarter company established reserves liabilities total amount million comprised million relation wholesaler inventory issues certain accounting matters million relation pharmaceutical pricing sales marketing practices addition company recorded charges million litigation matters recognized income million million income consists primarily million income patent defense cost reimbursement million litigation settlement income million settlement antitrust litigation involving vitamin manufacturers charges million primarily related buspar taxol proposed settlements additional information litigation see item financial statementsnote legal proceedings contingencies equity net income affiliates million compared million million respectively equity net income affiliates principally related companys joint venture sanofi investment imclone increase equity net income affiliates primarily reflects higher net income sanofi joint venture additional information equity net income affiliates see item financial statementsnote alliances investments expenses net income million million million respectively expenses include net interest expense interest income foreign exchange gains losses royalty income gains losses disposal property plant equipment decrease expenses primarily due net gains interest rate swaps increase expenses compared principally due higher interest expenses related borrowings billion related dupont pharmaceuticals imclone transactions business segments company operates four reportable segmentspharmaceuticals otn nutritionals healthcare otn previously included pharmaceuticals segment met quantitative thresholds reportable segment outlined sfas disclosure segments enterprise related information accordingly prior periods reclassified conform current year presentations percent companys sales segment follows total sales restated restated pharmaceuticals oncology therapeutics network nutritionals healthcare pharmaceuticals worldwide pharmaceuticals sales increased million reflecting price increase volume increase increase foreign exchange domestic sales increased million primarily due increased sales plavix pravachol franchise abilify total revenue glucovance paraplatin partly due impact sales workdown nonconsignment wholesaler inventory partially offset decreased sales glucophage ir taxol primarily due generic competition reyataz launched july million domestic sales international sales increased million including favorable foreign exchange impact primarily due increased sales pravachol taxol plavix avaproavalide analgesic products europe partially offset price declines principally germany italy worldwide pharmaceuticals sales decreased million reflecting price decline volume decline foreign exchange impact domestic sales declined million primarily due generic competition united states glucophage ir taxol buspar partially offset increased sales plavix addition products acquired dupont pharmaceuticals acquisition completed october addition decrease domestic pharmaceutical sales impacted buildup prior period inventory levels us wholesalers accounted consignment model subsequent workdown approximately million sales calculated net discounts rebates adjustments recognized year ended december reversed prior years international sales increased million significant foreign exchange impact primarily due increased sales pravachol plavix europe taxol japan addition products acquired dupont pharmaceuticals acquisition key pharmaceutical products sales include following total revenue abilify primarily domestic alliance revenue companys share net sales copromotion countries otsuka pharmaceutical co ltd otsuka million schizophrenia agent introduced united states november december achieved weekly new prescription share us antipsychotic market company received approval supplemental new drug application snda abilify maintaining stability patients schizophrenia announced submitted snda abilify treatment acute mania patients bipolar disorder us food drug administration fda abilify developed marketed bristolmyers squibb partner otsuka sales pravachol franchise increased including favorable foreign exchange impact million domestic sales increased million international sales increased including favorable foreign exchange impact million sales pravachol franchise increased million million sixmonth exclusivity extension granted april sales plavix platelet aggregation inhibitor increased including favorable foreign exchange impact million sales avaproavalide angiotensin ii receptor blocker treatment hypertension increased including favorable foreign exchange impact million sales plavix avaproavalide increased million million respectively sales plavix avaproavalide million million plavix avaproavalide cardiovascular products launched alliance bristolmyers squibb sanofi sales taxol paraplatin companys leading anticancer agents increased including favorable foreign exchange impact million million significant foreign exchange impact respectively international sales taxol increased including favorable foreign exchange impact million led strong sales japan france domestic sales taxol decreased million due generic competition domestic sales paraplatin increased million taxol sales decreased million million paraplatin sales increased million million sales sustiva antiretroviral agent treatment human immunodeficiency virusautoimmune immunodeficiency virus hivaids increased including favorable foreign exchange impact million million prior year international sales sustiva increased including favorable foreign exchange impact million sustiva acquired dupont pharmaceuticals october recorded sales million year monopril secondgeneration angiotensin converting enzyme ace inhibitor treatment hypertension increased sales including favorable foreign exchange impact reaching million monopril sales increased million million glucophage franchise sales increased million compared decrease million million glucophage ir oral medication treatment noninsulin dependent type diabetes saw sales decrease million decline glucophage ir due introduction generic metformin united states early glucophage ir sales decreased million million glucovance oral combination drug glucophage xr extended release tablets sales million million respectively compared sales million million respectively sales million million respectively sales zerit antiretroviral agent used treatment hivaids decreased including favorable foreign exchange impact million primarily result decreased demand due potential adverse side effects zerit sales decreased million million sales videxvidex ec antiretroviral agent used treatment hivaids increased including favorable foreign exchange impact million videxvidex ec sales increased million million sales serzone treatment depression decreased million result loss exclusivity labeling change indicating potential serious side effect product serzone sales decreased million million following table sets forth comparison reported net sales changes estimated total prescription growth retail mail order customers certain companys us pharmaceutical prescription products estimated prescription growth amounts based thirdparty data provided ims health supplier market research pharmaceutical industry significant portion companys domestic pharmaceutical sales made wholesalers changes reported net sales differ prescription growth change net sales may reflect underlying prescriber demand restated restated change change change change change change us us total us us total us us total net salesa prescriptionsb net salesa prescriptionsb net salesa prescriptionsb pravachol plavix avaproavalide sustiva na monopril glucovance glucophagexr zerit cefzil coumadin na videxvidex ec excess reflects change net sales dollar terms including change average selling prices wholesaler buying patterns b reflects change total prescriptions unit terms based thirdparty data earnings minority interest income taxes million increased million primarily due increased sales partially offset increased advertising product spending new existing inline products earnings minority interest income taxes million million respectively increase mainly due lower earnings result writeoff million acquired inprocess research development earnings unfavorably affected higher sales lower margin products full year impact generic competition glucophage ir taxol buspar united states oncology therapeutics network otn sales million increase prior year due volume growth manufacturers price changes sales increased million million otn sales accounted companys net sales respectively earnings minority interest income taxes million decreased slightly million million due margin erosion investments system infrastructure nutritionals nutritionals sales million increase increase due increase volume price increase partially offset decrease due foreign exchange international sales increased including unfavorable foreign exchange impact million million domestic sales increased million million worldwide childrens nutritionals sales increased including unfavorable foreign exchange impact million million result increase sales enfagrow primarily throughout pacific region million worldwide infant formula sales increased million significant foreign exchange impact primarily due increased sales enfamil companys largestselling infant formula international sales enfamil increased million million significant foreign exchange impact domestic sales enfamil increased million million mead johnson nutritionals mead johnson continues leader us infant formula market nutritionals sales remained consistent sales billion reflecting increase due price offset decrease due volume decrease due foreign exchange worldwide infant formula sales decreased million primarily specialty infant formula business worldwide sales enfamil decreased million million worldwide childrens nutritional sales increased including unfavorable foreign exchange impact million million result increase sales enfagrow primarily across pacific region million earnings minority interest income taxes nutritionals segment increased million million increase primarily due increased sales enfamil united states earnings minority interest income taxes nutritionals segment decreased million million result increased promotional spending sales force expenses related enfamil product line healthcare healthcare segment includes convatec medical imaging business consumer medicines united states japan sales healthcare segment increased million million healthcare sales increase result increase due volume increase changes selling prices increase due foreign exchange sales segment increased million including million sales medical imaging purchased october part dupont pharmaceuticals acquisition healthcare sales increase result increase due volume increase changes selling prices favorable foreign exchange impact healthcare sales business follows change restated restated dollars millions convatec medical imaging consumer medicines total healthcare excess increase convatec sales due increase including favorable foreign exchange impact worldwide sales ostomy products million strong growth worldwide wound care products increased including favorable foreign exchange impact million foreign exchange favorable effect sales increase convatec sales due increase worldwide sales ostomy products million strong growth worldwide wound care products increased million foreign exchange contributed sales increase increase medical imaging sales increase volume increase changes selling prices increase due foreign exchange worldwide sales cardiolite increased million million medical imaging business purchased october part dupont pharmaceuticals acquisition steady decline sales consumer medicines million million million part due distributors reducing inventory levels desirable levels consumption excedrin consumer brands remain flat earnings minority interest income taxes healthcare segment decreased million million primarily result unfavorable product mix inventory writeoffs excedrin quicktabs consumer medicines business earnings minority interest income taxes segment increased million million primarily due strong growth convatec business addition medical imaging business october geographic areas companys products available virtually every country world largest markets united states france japan germany spain italy canada sales united states increased primarily due increased sales plavix otn segment pravachol franchise abilify total revenue glucovance paraplatin sales increases partially offset continued impact generic competition united states glucophage ir taxol result loss exclusivity label change indicating potential serious side effect serzone sales united states decreased primarily due impact generic competition united states glucophage ir taxol buspar lesser extent buildup prior period inventory levels us wholesalers accounted consignment model subsequent workdown decrease partially offset increase plavix sales addition products acquired dupont dupont pharmaceuticals us pharmaceuticals sales million companys acquisition dupont pharmaceuticals completed october information us pharmaceuticals prescriber demand refer table within item businessbusiness segmentspharmaceutical segment sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys primary care pharmaceutical products sales europe middle east africa increased including increase foreign exchange result sales growth pravachol france taxol france germany spain italy analgesics france plavix germany spain avaproavalide italy sustiva spain favorable impact foreign exchange primarily due euro sales europe middle east africa increased including increase foreign exchange result strong growth pravachol france united kingdom plavix spain addition dupont pharmaceuticals products several markets region dupont pharmaceuticals sales region million sales western hemisphere countries increased including decrease foreign exchange primarily due increased sales plavix canada unfavorable impact foreign exchange primarily mexico brazil venezuela sales western hemisphere countries decreased including decrease foreign exchange unfavorable impact foreign exchange primarily brazil argentina underlying sales growth primarily due increased sales plavix canada nutritional products mexico pacific region sales increased including increase foreign exchange result increased sales taxol japan increased sales enfagrow throughout region sales pacific region increased including decrease foreign exchange products strong growth included taxol paraplatin japan nutritional products china indonesia developments february fda approved biologics license application bla erbitux anticancer agent company developing partnership imclone erbitux injection use combination irinotecan treatment patients epidermal growth factor receptor egfr expressing metastatic colorectal cancer refractory irinotecanbased chemotherapy use single agent treatment patients egfr expressing metastatic colorectal cancer intolerant irinotecanbased chemotherapy accordance agreement company paid imclone million march milestone payment approval erbitux fda january company announced agreed acquire acordis specialty fibres acordis privately held company based united kingdom licenses patent rights supplies materials convatec wound therapeutics line transaction subject regulatory approval received transaction completed company expects record inprocess research development charge million million december company confirmed mead johnson wholly owned subsidiary company reached agreement novartis ag sell novartis adult nutritional business brands trademarks patents intellectual property rights million including million contingent product conversion million upfront payment supply agreement transaction closed february pretax gain approximately million expected recorded first quarter adult nutritional products recorded sales million december company lexicon genetics incorporated lexicon formed broad alliance drug discovery development commercialization neuroscience field alliance designed accelerate discovery development breakthrough therapies address significant unmet medical needs psychiatry neurology company made expensed initial payment million october company corgentech inc biotechnology company entered agreement jointly develop commercialize corgentechs ef decoy edifoligide treatment prevention vein graft failure following coronary artery bypass graft peripheral artery bypass graft surgery product currently phase iii clinical trials fda granted fast track status indications company made expensed initial payment million potential clinical regulatory milestone payments million arrangements profit sharing august pravigard pac buffered aspirin pravastatin sodium tablets launched united states july reyataz protease inhibitor treatment hivaids launched united states march company received marketing approval reyataz eu august company entered licensing commercialization agreement flamel technologies sa develop market basulin first controlled release unmodified human insulin developed oncedaily injection patients type type diabetes basulin entering phase ii clinical development agreement company lead assume cost future development manufacturing efforts basulin exclusive worldwide rights product company made expensed initial payment million october potential additional million clinical regulatory milestone payments time royalty payments product sales financial position liquidity capital resources cash cash equivalents marketable securities totaled approximately billion december compared billion december approximately billion cash cash equivalents marketable securities held companys foreign subsidiaries company expect repatriate foreseeable future company expects cash generated us operations together borrowings capital markets sufficiently cover cash needs working capital capital expenditures dividends us repatriation united states would require additional tax provisions reflected consolidated financial statements discussion matter see critical accounting policiesincome taxes working capital increased billion december billion december primarily result increase marketable securities decrease commercial paper outstanding partially offset increased accrued expenses cash cash equivalents marketable securities conversion workingcapital items borrowings expected fund nearterm operations cash cash equivalents december primarily consisted us dollar denominated bank deposits original maturity three months less marketable securities december primarily consisted us dollar denominated floating rate instruments aaaaaa credit rating due nature instruments company considers reasonable expect fair market values significantly impacted change interest rates liquidated cash short notice average interest yield cash cash equivalents december respectively interest yields marketable securities averaged respectively longterm debt december denominated primarily us dollars also included japanese yen longterm debt million longterm debt increased billion december billion december primarily due billion fixed rate notes billion floating rate convertible debentures issued august october respectively proceeds issuances used repay shortterm borrowings fund cash needs us operations convertible debentures mature callable par time september issuer convertible company common stock shares per debenture per share subject increases maximum shares per debenture based increases market price stock per share plus antidilution certain adjustments interest payable quarterly annual rate equal month libor reset quarterly minus majority companys debt fixed rate company however entered fixed floating interest rate swaps billion longterm debt interest expense million million million respectively us commercial paper outstanding december us commercial paper outstanding december million average interest rate average interest rate year ended december international shortterm borrowings respectively current installments longterm debt respectively december company two revolving credit facilities totaling billion aggregate support domestic commercial paper program facilities established september august respectively syndicate lenders extendable anniversary date consent lenders one revolving credit facilities certain financial covenants company compliance december borrowings outstanding revolving credit facilities december company unused shortterm lines credit foreign banks million million december respectively july standard poors lowered longterm credit rating company aa aa addition standard poors affirmed short term rating april moodys investors service lowered companys longterm credit rating aa march moodys affirmed prime shortterm credit rating company march standard poors placed longterm shortterm ratings company watch negative implications moodys longterm credit rating remains negative outlook net cash provided operating activities approximately billion billion billion increase attributable higher net earnings income tax payments primarily related gain arising sale clairol business cash flow operations also included pension contributions million million million respectively cash provided operations borrowings primarily used past three years pay dividends billion repurchase million shares cost billion company also invested billion past three years capital expansion improve plant efficiency maintain superior research facilities company purchase common stock company repurchased million million shares common stock cost million million respectively bringing total shares acquired since share repurchase programs inception million shares share repurchase program authorizes company purchase common stock time time open market private transactions market conditions permit program intended reduce increase shares outstanding option exercises obtain shares general corporate purposes employment levels december remained constant compared prioryear levels dividends declared per common share years december company declared quarterly dividend per common share indicated dividend full year per share companys financial condition liquidity could affected obligations make milestone onetime payments outcome pending litigations investigations including challenge plavix patent information see item financial statementsnote alliances investments note legal proceedings contingencies contractual obligations payments due period companys contractual obligations december follows obligations expiring period later total years dollars millions shortterm borrowings longterm debt capital leases operating leases purchase obligations imclone milestone payment standby letters credit longterm liabilities total obligations included shortterm borrowings companys consolidated balance sheet december balances represent outstanding nominal longterm debt values addition company committed make potential future milestone payments thirdparties part inlicensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded companys consolidated balance sheet discussion contractual obligations reference made item financial statementsnote shortterm borrowings longterm debt note financial instruments note leases note pension postretirement benefit plans offbalance sheet arrangements march company imclone revised agreement reducing total payment million billion pursuant agreement company paid imclone million million million accordance agreement company paid imclone million march milestone payment approval erbitux fda pay additional million erbitux approved use second tumor type discussion companys agreement imclone see item financial statementsnote alliances investments recently issued accounting standards january financial accounting standards board fasb issued staff position fas accounting disclosure requirements related medicare prescription drug improvement modernization act act act introduces prescription drug benefit medicare well federal subsidy sponsors retiree health care benefit plans provide benefit least actuarially equivalent medicare part present detailed regulations necessary implement act including account federal subsidy issued company elected defer recognizing effects act authoritative guidance accounting federal subsidy issued december staff securities exchange commission sec issued staff accounting bulletin sab revenue recognition supersedes sab revenue recognition financial statements sab primary purpose rescind accounting guidance contained sab related multiple element revenue arrangements superseded result issuance eitf accounting revenue arrangements multiple deliverables additionally sab rescinds secs revenue recognition financial statements frequently asked questions answers faq issued sab codified sec topic revenue recognition wording sab changed reflect issuance eitf revenue recognition principles sab remain largely unchanged issuance sab initial adoption accounting pronouncement material effect companys consolidated financial statements december fasb amended statement financial accounting standards sfas employers disclosures pensions post retirement benefits amended statement revises employers disclosures pension plans postretirement benefit plans change measurement recognition plans required fasb statements employers accounting pensions employers accounting settlements curtailments defined benefit pension plans termination benefits employers disclosures postretirements plans pensions revisions included amended statement effective financial statements fiscal years ended december company provided required disclosures see item financial statementsnote pension postretirement benefit plans note legal proceedings contingencies december fasb revised interpretation consolidation variable interest entities fin fin requires variable interest entity consolidated company company subject majority risk loss variable interest entitys activities entitled receive majority entitys residual returns fin also requires disclosures variable interest entities company required consolidate significant variable interest consolidation requirements fin revised apply immediately variable interest entities created january existing entities first fiscal year interim period beginning march certain disclosure requirements apply financial statements issued january regardless variable interest entity established initial adoption accounting pronouncement material effect consolidated financial statements may fasb issued sfas accounting certain financial instruments characteristics liabilities equity sfas establishes standards issuer classifies measures certain financial instruments characteristics liabilities equity statement requires issuer classify financial instrument within scope liability initial adoption accounting pronouncement affect consolidated financial statements may emerging issues task force reached consensus issue revenue arrangements multiple deliverables issue addresses certain aspects accounting vendor arrangements perform multiple revenue generating activities companys revenue recognition policies already conformed requirements consensus initial adoption affect consolidated financial statements april fasb issued sfas amendment statement derivative instruments hedging activities sfas amends sfas requiring contracts comparable characteristics accounted similarly specifically statement clarifies circumstances contract initial net investment meets characteristics derivative clarifies derivative contains financing component amends definition underlying conform interpretation guarantors accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin discussed amends certain existing pronouncements initial adoption accounting pronouncement material effect consolidated financial statements december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amends sfas accounting stockbased compensation provide alternative methods transition voluntary change fair value based method accounting stockbased employee compensation addition sfas amends disclosure requirements sfas require prominent disclosures annual interim financial statements method accounting stockbased employee compensation effect method used reported results provisions sfas effective financial statements year ended december sfas material impact companys consolidated financial statements adoption standard require company change company plan change fair value based method accounting stockbased compensation november fasb issued fin fin requires guarantor recognize liability inception guarantee fair value obligation undertaken issuing guarantee include detailed disclosure respect guarantees types contracts company enters meet scope interpretation financial performance standby letters credit behalf wholly owned subsidiaries fin effective guarantees issued modified december initial adoption accounting pronouncement material effect companys consolidated financial statements retirement benefits plan description company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan principal defined contribution plan bristolmyers squibb savings investment program approximately total company defined benefit pension plan assets liabilities held us plans assets us plans held single trust common asset allocation unless specified otherwise references section total company plans us plans together international plans benefits companys defined benefit pension plans based primarily years credited service participants compensation assets companys defined benefit plans consist primarily equity fixedincome securities december fair market value plan assets companys defined benefit plans increased million million december us plans assets allocated equity securities compared end fixed income securities compared end private equity investments compared end bristolmyers squibb common stock represented less assets us plans end company provides comprehensive medical group life benefits substantially us retirees elect participate companys comprehensive medical group life plans asset allocation postretirement plans identical asset allocation described us defined benefit pension plans accrual accounting significant assumptions consistent requirements sfas employers accounting pensions company accounts pension benefits using accrual method recognizing pension expense payment benefits retirees accrual method accounting pension benefits necessarily requires actuarial assumptions concerning future events determine amount timing benefit payments companys key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect accumulated benefit obligations future cash funding actual results given year may differ estimated economic factors assumed discount rate used company determining future pension obligations us plans based indices aa aaarated corporate bonds indices high quality corporate bonds selected reflect weightedaverage remaining period benefit payments assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors net pension expense companys defined benefit pension plans included earnings minority interest income taxes million compared million us plans pension expense determined using assumed discount rate assumed rate compensation increase present value benefit obligations december us plans determined using assumed discount rate assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining accumulated benefit obligation december reduced accumulated benefit obligation would increased million us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million actual rates return earned us plan assets last ten years follows year return year return discussed gaap provides differences expected actual returns recognized average future service employees december company lowered assumed discount rate us plans assumed rate compensation increase raised following review recent experience compensation assumed increase scale different rates different ages rate disclosed december single rate used age would produce present value benefit obligations methodology disclosure used calculating rate december rate december reduction discount rate increase assumed rate compensation increase effect increasing present value benefit obligations accordingly effect increasing pension expense addition company revised based upon review experience assumption active mortality revision effect increasing present value benefit obligations accordingly effect increasing pension expense december company lowered assumed discount rate us plans reflect decline yields high quality corporate bonds assumed rate compensation decrease reflect expectations lower inflation future consistent reduction assumed discount rate reduction assumed discount rate increased present value future benefit obligations accordingly effect increasing us plans pension expense contrast reduction assumed rate compensation increase decreased present value benefit obligations accordingly effect decreasing us plans pension expense addition company revised based change expectations future terminations retirements retirement turnover assumptions revision decreased present value benefit obligations pension expense following many years strong performance global equity market fell sharply sp declined cumulative reversed sp rose company reduced expected rate return us plan assets december maintained throughout company expects net pension expense defined benefit pension plans included earnings minority interest income taxes approximately million higher million reflecting among things decrease assumed discount rate increase assumed rate compensation increase decrease marketrelated value assets companys defined benefit pension plans rise global equity markets improved funded status plans three difficult years since investment gains losses recognized marketrelated value assets period years however negative impact period felt following putting upward pressure pension expense company used assumed discount rates expected longterm rates return plan assets calculating cost pension benefits cost postretirement benefits except case discount rate december rate used pension benefits versus postretirement benefits reflect shorter duration postretirement liabilities us health care costs retiree population assumed increase trend expected increase per year actual costs higher assumed likely put significant upward pressure companys expense retiree health care december president bush signed law medicare prescription drug improvement modernization act following guidance fasb staff position fas company elected defer recognition effect act accumulated postretirement benefit obligation net periodic postretirement benefit cost reflect effect act plan specific authoritative guidance accounting federal subsidy pending fasb guidance issued could require change previously reported information delayed recognition actuarial gains losses december unrecognized net actuarial losses companys defined benefit plans million million respectively based fair market value plan assets unrecognized net actuarial losses reflect part decline fair market value plan assets reduction weightedaverage discount rate sfas provides delayed recognition actuarial gains losses including amounts arising changes estimated plan benefit obligations due changes assumed discount rate differences actual expected returns plan assets assumption changes sfas requires unrecognized net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value systematic rational manner five years amortized pension income expense year extent unrecognized net actuarial loss gain exceeds greater projected benefit obligation marketrelated value plan assets beginning year net gains losses recognized pension income expense prospectively period approximates average remaining service period active employees expected receive benefits plans approximately years extent offset losses gains subsequent years december unrecognized net actuarial loss determined based marketrelated value plan assets million amount exceeded greater projected benefit obligation market related value plan assets million december unrecognized net actuarial loss determined based marketrelated value plan assets million amount exceeded greater projected benefit obligation market related value plan assets million unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization million unrecognized loss expected increase pension expense following ten years approximately million per year amount reflected higher expense expected event fair market value pension plan assets particular plan less accumulated benefit obligation plan yearend gaap may require additional minimum liability circumstances reduction stockholders equity establishment intangible asset december fair market value companys defined benefit pension plan assets million related accumulated benefit obligation million company recognized additional minimum liability million cumulative million december offset million charge comprehensive income included stockholders equity december fair market value companys defined benefit pension plan assets million related accumulated benefit obligation million company recognized additional minimum liability million cumulative million december offset creation million intangible asset million charge comprehensive income included stockholders equity plan funding companys funding policy defined benefit plans contribute amounts provide current service fund past service liability company contributed defined benefit plans million million respectively critical accounting policies company prepares financial statements conformity accounting principles generally accepted united states preparation financial statements conformity gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period companys critical accounting policies important companys financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following represent critical accounting policies summary companys significant accounting policies including critical accounting policies discussed see item financial statementsnote accounting policies management companys independent accountants discussed companys critical accounting policies audit committee board directors revenue recognition companys accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue sales substantially risks rewards ownership transferred customer except case certain transactions us pharmaceuticals wholesalers accounted using consignment model gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue net discounts rebates sales allowances accruals returns involve significant estimates judgments consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers fifo basis companys estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products well companys analysis thirdparty information including information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data companys internal information companys estimates subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflect limitations acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants entitled assets acquired business combination used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital impairment longlived assets accordance sfas accounting impairment disposal longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value goodwill evaluated least annually impairment accordance sfas goodwill intangible assets sfas requires goodwill tested impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value estimates future cash flows based reasonable supportable assumptions projections require managements judgment changes key assumptions companys businesses prospects changes market conditions could result impairment charge equity investments company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers accounting principles board opinion equity method accounting investments common stock sets forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment companys investment imclone subject accounting see item financial statementsnote alliances investments discussion companys investment imclone retirement benefits companys pension plans postretirement benefit plans accounted using actuarial valuations required sfas employers accounting pensions sfas employers accounting postretirement benefits pensions company considers accounting retirement plans critical management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect accumulated benefit obligations future cash funding detailed discussion companys retirement benefits see retirement benefits item financial statementsnote pension postretirement benefit plans restructuring downsize streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates resulting adjustment earnings contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including government investigations shareholders suits product liability environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussion contingencies see item financial statementsnote income taxes note legal proceedings contingencies income taxes december taxes provided approximately billion undistributed earnings foreign subsidiaries company invested expects invest undistributed earnings indefinitely future earnings repatriated united states company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company evaluates need deferred tax asset valuation allowance assessing whether likely realize deferred tax assets future assessment whether valuation allowance required often requires significant judgment including forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowance made earnings period assessment made addition company operations tax jurisdictions located areas world subject audit jurisdictions tax audits nature often complex require several years resolve accruals tax contingencies require management make estimates judgments respect ultimate outcome tax audit actual results could vary estimates outlook company expects growth opportunities exclusivity challenges next several years estimates reductions net sales range billion levels products lost lose exclusivity protections specifically metformin franchise united states taxol europe monopril united states canada pravastatin certain countries europe paraplatin united states serzone united states sales rose resulting higher base generic competition develop expected thereby increasing expected level exclusivity losses addition impact exclusivity losses paraplatin anticipated occur primarily accelerated anticipated sixmonth extension exclusivity protection based pediatric studies obtained april amounts sales reductions exclusivity losses realization particular periods eventual levels remaining sales revenues uncertain dependent levels sales time exclusivity protection ends timing degree development generic competition speed approvals market entry impact factors subject uncertainties company estimates incremental exclusivity losses measured net sales levels time exclusivity lost billion billion years company believes revenue loss less offset growth revenues resulting growth companys inline products including plavix avaproavalide sustiva growth recently launched exclusive products abilify reyataz growth recently fda approved product erbitux introduction latestage pipeline products abatacept entecavir muraglitazar may approved within next thirtysix months begin contribute significantly additionally otn sales growth expected continue belief subject competitive factors including relating pravachol adverse determination may occur respect plavix patent litigation see item businesscompetition item financial statementsnote legal proceedings contingencies addition assurance company obtain required regulatory approvals latestage pipeline products company expects resulting product mix pressure company margins products losing exclusivity protection carry higher margins products expected grow sales pravachol statin cholesterol companys largest product net sales product beginning lose exclusivity markets loss us exclusivity expected rate decline market share could accelerated recent clinical studies company historically reviewed continue review cost base decisions may taken result reviews may result restructuring charges later year future periods time company expects invest behind inline products research development pipeline particularly latestage products reflected earnings guidance external development licensing remain important elements companys strategy potential cost impact transactions may entered future built companys plans guidance respect earnings company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity additional discussion matter see item financial statementsnote legal proceedings contingencies companys expectations future sales growth described include substantial expected increases sales plavix net sales approximately billion composition matter patent plavix expires currently subject litigation united states similar proceedings involving plavix also instituted outside united states company continues believe patent valid infringed alliance partner patentholder sanofi vigorously pursuing cases possible time reasonably assess outcome litigations adverse determination litigations timing potential generic competition plavix however generic competition occur company believes unlikely occur sometime loss market exclusivity plavix subsequent development generic competition would material companys sales plavix results operations cash flows could material financial condition liquidity actual results may differ materially experience described factors could affect expectations described cautionary factors may affect future results cautionary factors may affect future results annual report including documents incorporated reference written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years although possible predict identify factors may include limited following new government laws regulations health care reform initiatives united states state federal level countries ii changes fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available united states certain foreign countries iv new laws regulations judicial decisions affecting pricing marketing within across jurisdictions v changes intellectual property law competitive factors new products developed competitors lower prices superior performance features otherwise competitive bristolmyers squibbs current products ii generic competition companys products mature patents expire products iii technological advances patents attained competitors iv problems licensors suppliers distributors v business combinations among companys competitors major customers difficulties delays inherent product development manufacturing sale products may appear promising development fail reach market number reasons including efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture ii failure products achieve maintain commercial viability iii seizure recall products iv failure obtain imposition limitations use loss patent intellectual property rights v failure company vendors suppliers comply current good manufacturing practices application regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing vi manufacturing distribution problems legal difficulties including lawsuits claims proceedings investigations preclude delay commercialization products adversely affect operations profitability liquidity financial condition including intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii inability obtain adequate insurance respect type liability iv recalls pharmaceutical products forced closings manufacturing plants v government investigations including relating wholesaler inventory financial restatement product pricing promotion vi claims asserting violations securities antitrust federal state pricing laws vii environmental matters viii tax liabilities assurance increase scope matters future lawsuits claims proceedings investigations material increasing pricing pressures worldwide including rules practices managed care groups institutional governmental purchasers judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement pricing general fluctuations buying patterns inventory levels major distributors retail chains trade buyers may result seasonality pricing wholesaler buying decisions including effect incentives offered companys wholesaler inventory management policies including workdown changes wholesaler inventory levels factors greater expected costs difficulties including unanticipated effects difficulties acquisitions dispositions events including obtaining regulatory approvals connection evolving business strategies legal defense costs insurance expense settlement costs risk adverse decision related litigation changes advertising promotional spending categories spending may affect sales changes product mix may affect margins changes companys structure operations revenues costs staffing efficiency resulting acquisitions divestitures mergers alliances restructurings strategic initiatives economic factors company control changes business economic conditions including limited changes interest rates fluctuation foreign currency exchange rates changes business political economic conditions due political social instability military armed conflict nationalization assets debt payment moratoriums restrictions commerce actual threatened terrorist attacks united states parts world related military action changes accounting standards promulgated fasb sec american institute certified public accountants may require adjustments financial statements capacity efficiency reliability security potential breakdown invasion destruction interruption information systems reliance company vendors partners third parties meet contractual regulatory obligations relation arrangements company results clinical studies relating companys competitors products although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes gains losses hedging transactions offset gains losses underlying exposures hedged ineffective portion hedges reported earnings occurs foreign exchange option contracts forward contracts used hedge anticipated transactions companys primary foreign currency exposures relation us dollar euro japanese yen canadian dollar mexican peso table summarizes companys outstanding foreign exchange contracts december fair value foreign exchange contracts based yearend currency rates blackscholes model case option contracts fair value option contracts forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weighted average notional fair strike price amount value maturity dollars millions except currency rates foreign exchange forwards australian dollar brazilian real british pound canadian dollar euro japanese yen south african rand swedish krona swiss franc total contracts december company held option contracts aggregate notional amount fair value million million respectively contracts granted right sell euros canadian australian dollars company also held forward contracts aggregate notional amount million fair value liability million contracts primarily related exposures euro company uses derivative instruments part interest rate risk management policy derivative instruments used include interest rate swaps subject fairvalue hedge accounting treatment company executed several fixed floating interest rate swaps convert billion companys fixed rate debt paid variable rate debt year ended december company recognized net reduction interest expense million reflects benefit lower floating rate obtained swap agreement sfas requires revaluation fair value swap contracts well underlying debt hedged swap contracts underlying debt revalued resulting increase current assets longterm debt million swap contracts generally held maturity used speculative purposes following table summarizes interest rate swaps outstanding december dollars millions notional amount underlying debt variable rate received maturity fair value interest rate contracts swaps associated notes due month us libor swaps associated notes due month us libor swaps associated notes due month us libor swaps associated notes due month us libor following table summarizes interest rate swaps outstanding december dollars millions notional amount interest rate contracts underlying debt variable rate received maturity fair value swaps associated notes due month usli bor swaps associated notes due month us libor estimated change interest rate structure would material impact companys consolidated financial position results operations cash flows company also outstanding several interest rate foreign currency swaps related japanese yen notes due aggregate fair value instruments december million million respectively company million million longterm debt outstanding december respectively see item financial statementsnote shortterm borrowings longterm debt note financial instruments additional information company maintains cash cash equivalents marketable securities various financial institutions order limit exposure one financial institution financial institutions headquartered primarily north america europe bristolmyers squibb company consolidated statement earnings millions except per share data item financial statements supplementary data year ended december restated restated earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items litigation charges net gain sales businessesproduct lines asset impairment charge investment imclone equity net income affiliates expense net total expenses earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations net earnings net gain disposal net earnings earnings per common share basic earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements bristolmyers squibb company consolidated statement comprehensive income retained earnings dollars millions restated restated comprehensive income net earnings comprehensive income foreign currency translation net tax benefit deferred losses derivatives qualifying hedges net tax benefit minimum pension liability adjustment net tax benefit available sale securities net taxes total comprehensive income comprehensive income retained earnings retained earnings january net earnings cash dividends declared zimmer common stock dividend retained earnings december accompanying notes integral part financial statements bristolmyers squibb company consolidated balance sheet dollars millions december restated assets current assets cash cash equivalents marketable securities receivables net allowances inventories including consignment inventory deferred income taxes net valuation allowances prepaid expenses total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities deferred revenue consigned inventory total current liabilities liabilities longterm debt total liabilities commitments contingencies stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares issued capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock common shares total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements bristolmyers squibb company consolidated statement cash flows dollars millions year ended december restated restated cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization provision deferred income taxes acquired inprocess research development litigation charges asset impairment charge investment imclone provision restructuring items gain sales businessesproduct lines including discontinued operations loss gain disposal property plant equipment equity net income affiliates impairment charges asset writeoffs litigation settlement payments net receipts minority interest net distributions taxes pension contributions changes operating assets liabilities receivables inventories prepaid expenses assets deferred revenue consigned inventory accounts payable accrued expenses us foreign income taxes payable liabilities net cash provided operating activities cash flows investing activities proceeds sales maturities marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds disposal property plant equipment proceeds sales businessesproduct lines proceeds sale clairol purchase dupont pharmaceuticals clairol dupont pharmaceuticals divestiture acquisition costs investments companies purchases trademarks patents licenses net cash used investing activities cash flows financing activities shortterm borrowings net repayments longterm debt borrowings longterm debt repayments issuances common stock stock plans purchases treasury stock dividends paid net cash used provided financing activities effect exchange rates cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part financial statements bristolmyers squibb company notes consolidated financial statements note accounting policies throughout notes consolidated financial statements certain prior periods prior period comparisons reflect balances amounts restated basis information restatement see note restatement previously issued financial statements years ended december basis consolidation consolidated financial statements include accounts bristolmyers squibb company bms company bristolmyers squibb controlled majority owned subsidiaries intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation including reclassification amounts relating equity net income affiliates formerly netted minority interest net taxes presented separate line consolidated statement earnings see also investments use estimates preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities well estimates used applying revenue recognition policy accounting retirement postretirement benefits including actuarial assumptions actual results could differ estimated results revenue recognition company recognizes revenue substantially risks rewards ownership transferred customer case certain sales made nutritionals healthcare segments certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser revenues reduced time sale reflect expected returns estimated based historical experience additionally provisions made time sale discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout fifo basis companys estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products well companys analysis thirdparty information including information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data companys internal information companys estimates subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflect limitations sales rebate return accruals medicaid rebate accruals million million december respectively managed healthcare rebate accruals million million december respectively rebate accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals established similar manner recorded reduction accounts receivable million million december respectively bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized company record provision income taxes undistributed earnings foreign subsidiaries expect repatriate foreseeable future company establishes liabilities possible assessments taxing authorities resulting known tax exposures amounts represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known cash cash equivalents cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value marketable securities company accounts marketable securities accordance statement financial accounting standards sfas accounting certain investments debt equity securities company determined appropriate classification marketable securities availableforsale time purchase december companys investments marketable securities reported fair value unrealized gains losses reported component accumulated comprehensive income loss stockholders equity amortized cost debt securities adjusted amortization premiums accretion discounts date purchase maturity amortization included interest income addition deduction coupon interest earned investments company follows investment managers method determining cost basis computing realized gains losses sale availableforsale securities average cost method realized gains losses included income expense marketable securities classified available sale recorded cost approximates fair value inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable impairment longlived assets effective january company adopted provisions sfas accounting impairment longlived assets adoption sfas material effect consolidated financial statements company sfas establishes accounting impairment longlived tangible intangible assets goodwill disposal segment business pursuant sfas company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges four ten years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included assets million million december respectively investments january company adopted financial accounting standards board fasb interpretation fin interpretation consolidation variable interest entities interpretation arb fin clarifies application accounting research bulletin arb consolidated financial statements certain entities equity investors characteristics controlling financial interest sufficient equity risk entity finance activities without additional subordinated financial support parties entities known variable interest entities vies fasb issued revision fin fin r december fin r effective interim period ending march new existing vies adoption fin effect companys financial statements entity meet definition vie fin company accounts entity provisions accounting principles board apb opinon number equity method accounting investments common stock requires company consolidates majority owned subsidiaries ability exercise control company accounts less owned companies ability exercise significant influence using equity method accounting companys share net income losses equity investments included equity net income affiliates consolidated statement earnings company periodically reviews equity investments impairment adjusts investments fair value decline market value deemed temporary company recorded asset impairment charge million otherthantemporary decline market value imclone systems incorporated imclone longterm investments securities comprise marketable equity securities securities investments market values readily available included assets marketable equity securities classified availableforsale reported fair value fair value based quoted market prices end reporting period securities investments market values readily available carried cost unrealized gains losses reported net related tax effects component accumulated comprehensive income loss stockholders equity sold time sale gains losses calculated specific identification method recognized incomeexpense losses also recognized income decline market value deemed temporary goodwill intangible assets company adopted sfas goodwill intangible assets january certain provisions adopted july respect amortization goodwill arising acquisitions made june sfas addresses initial recognition measurement intangible assets acquired outside business combination recognition measurement goodwill intangible assets subsequent acquisition new rules goodwill longer amortized subject annual impairment tests connection accounting change goodwill resulting companys acquisition dupont pharmaceuticals business dupont pharmaceuticals investment imclone amortized goodwill arising business acquisitions prior july amortized straightline basis periods ranging years goodwill amortized effective january goodwill amortization expense million accordance sfas goodwill tested impairment upon adoption new standard annually thereafter sfas requires goodwill tested impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value company completed goodwill impairment assessment indicated impairment goodwill bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued intangible assets consisting patents trademarks technology licenses amortized straightline basis useful lives ranging years sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value intangible assets evaluated impairment accordance sfas described impairment longlived assets product liability accruals product liability recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation charges consolidated statement earnings contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others product liability environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussion contingencies reference made note income taxes note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized charge credit earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded comprehensive income loss subsequently recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statement earnings shipping handling costs company typically charge customers shipping handling costs shipping handling costs included marketing selling administrative expenses million million million respectively advertising costs advertising costs expensed incurred advertising expense million million million respectively milestone payments company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners contingent upon achievement certain predetermined criteria milestones achieved prior marketing approval product payments expensed research development product approval additional milestones capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability whenever events changes circumstances indicate carrying amounts may recoverable bristolmyers squibb company notes consolidated financial statements continued note accounting policies continued acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants entitled assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options convertible instruments stock compensation plans company applies apb opinion accounting stock issued employees related interpretations accounting stockbased compensation plans company recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date grants restricted stock company recognizes compensation expense straightline basis period restrictions expire following table summarizes companys results pro forma basis recorded compensation expense based upon fair value grant date awards plans consistent methodology prescribed sfas accounting stockbased compensation restated restated dollars millions except per share data net earnings reported deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma basic earnings per share reported pro forma diluted earnings per share reported pro forma see note stockholders equity additional information bristolmyers squibb company notes consolidated financial statements continued note restatement previously issued financial statements years ended december company restated consolidated balance sheet december consolidated statements earnings cash flows comprehensive income retained earnings years ended december restatement affected periods prior impact restatement prior periods reflected adjustment retained earnings january addition restatement impacts first second third quarters restated amounts quarters comparable interim periods presented note selected quarterly financial data unaudited restatement corrects certain companys historical accounting policies conform gaap ii corrects certain errors made application gaap set forth restatement adjustments included restatement previously issued financial statements years ended december error within meaning apb opinion accounting changes following table presents impact restatement adjustments described net earnings years ended december retained earnings january net earnings retained year ended earnings december january dollars millions reported wic rebates accrual goods transit net sales adjustments international pension employee benefit plan accrual intercompany accounts marketing selling administrative adjustments intercompany foreign exchange gains losses restatement items adjustments minority interest net taxes provision income taxes restated adjustments net sales related adjustments cost products sold wic rebates accrual historically company accrued rebates women infants children wic program date coupons issued states error application gaap requires accrual date sale product company corrected policy accrue wic rebates date sale goods transit company corrected error application gaap regarding timing revenue recognition certain sales made mead johnson nutritionals mead johnson unit healthcare unit certain nonus pharmaceuticals units company previously recorded revenue products sold date shipment records revenue based terms sale date receipt purchaser net sales adjustments company corrected error accounting managed health care sales rebate accrual amounts initially recorded connection companys previous restatement company restated certain sales transactions made certain asia business units revenue recognized error prior transfer substantially risks rewards ownership due existence right return available purchaser product company erroneously failed adjust timely basis accrual sales returns charge backs deductions sales products divested division made prior divestiture required gaap adjustments earnings continuing operations minority interest income taxes international pension employee benefit plan accrual historically company erroneously accounted certain international employee benefit plans cash nongaap methods based belief impact applying accrual method required gaap immaterial company actuarial analysis performed larger plans determined understated benefits liabilities plans company accounts pension bristolmyers squibb company notes consolidated financial statements continued note restatement previously issued financial statements years ended december continued employee benefit plans accrual method addition company failed make required accrual one international employee benefit plans due misapplication gaap intercompany accounts company determined certain unreconciled intercompany accounts payable receivable aggregating net balance million written prior january marketing selling administrative adjustments company recorded number adjustments respect marketing selling administrative expense company determined error application historical accounting policy accruing earned vacation yet taken company determined properly recorded expense training operational support relating contract third party period incurred company wrote certain accounts adequate documentation supporting existence company also wrote reserves postemployment benefits pensions retained error certain divested businesses company incorrectly capitalized certain costs related internally developed software due misapplication gaap company also failed adjust certain expense reserves timely basis actual amount expense incurred required gaap company also corrected number smaller immaterial errors application gaap intercompany foreign exchange gains losses historically company deferred gains losses certain intercompany foreign exchange loan transactions recording gains losses accumulated comprehensive loss companys consolidated balance sheet error application gaap requires unless intercompany transaction longterm investment settlement planned foreseeable future foreign currency transaction gain loss included determining net income company corrected policy comply gaap restatement items company several foreign subsidiaries operate jurisdictions hyperinflationary currencies respect company recorded restatement adjustments correct errors relating accounting deferred tax assets liabilities valuation allowances result company record foreign exchange gain loss respect deferred tax assets error company erroneously overaccrued expenses relating certain grants completed failing adjust accruals actual amounts expenses incurred life grants company failed writeoff unreconciled account relating acquisition dupont pharmaceuticals company also failed adjust certain expense reserves timely basis actual amount expense incurred required gaap company also corrected number smaller immaterial errors application gaap adjustments minority interest net taxes company recorded duplicate deferred tax net assets error related tax attributes certain partnership entities sanofisynthelabo sanofi owns majority controlling interest adjustments provision income taxes contingency reserves certain instances periods restated company made errors recording reserves tax contingencies company believes may inappropriate adjustments tax contingency reserves company completed review able determine whether errors tax contingency reserves corrected restatement related inappropriate accounting us federal state tax items company identified number errors related current deferred federal state taxes corresponding current deferred tax expense errors included establishing deferred tax assets extent necessary corresponding valuation allowances net operating loss tax credit carryforwards ii applying misapplying asset liability approach deferred taxes required gaap iii considering relevant information date issuance financial statements iv timely adjusting differences tax provisions filed tax returns foreign tax items company identified number errors related current deferred foreign taxes corresponding tax expense errors included establishing deferred tax assets extent necessary corresponding valuation allowances net operating loss tax credit carryforwards ii applying misapplying asset liability approach deferred taxes required gaap iii considering information available date issuance financial statements iv timely adjusting filed tax returns v accounting income taxes certain jurisdictions cash basis bristolmyers squibb company notes consolidated financial statements continued note restatement previously issued financial statements years ended december continued following table presents impact restatement adjustments described provision income taxes earnings minority interest income taxes provision income taxes previously reported contingency reserves tax items us nonus provision income taxes restated following table presents impact income tax restatement adjustments described companys consolidated balance sheet december contingency tax reserves items assets deferred income taxes current deferred income taxes noncurrent liabilities accrued liabilities us foreign income taxes payable adjustments cash cash equivalents classification company determined certain investments cash management program erroneously classified cash equivalents consolidated balance sheet december statement cash flows fiscal years respectively approximately billion billion investments held company reflected cash cash equivalents companys consolidated balance sheet december respectively although company believes investments highly liquid maturities investments exceeded three months previous presentation cash cash equivalents error company restated prior periods present investments marketable securities restatement adjustment companys consolidated balance sheet december decreased amount cash cash equivalents approximately billion restatement adjustment statements cash flows increased amount net cash used investing activities years ended december approximately billion billion respectively adjustments expense net classification table presents restatement charges credits certain amounts classified error reclassified part restatement expense net appropriate line item consolidated statement earnings years ended december year ended december dollars millions total adjustments expense net net sales rebate accrual adjustment cost products sold royalty expense product liability expense royalties receivable writeoff adjustment neta marketing selling administrative amortization capitalized software restricted stock grant amortization neta advertising product promotion neta research development reimbursement clinical study expenditures neta equity net income affiliates imclone share losses certain items included net reclassifications amounts errors within meaning apb opinion accounting changes rather amounts reclassified conform current year presentation bristolmyers squibb company notes consolidated financial statements continued note restatement previously issued financial statements years ended december continued following table presents impact restatement adjustments companys previously reported results condensed basis previously previously reported restated reported restated dollars millions except per share data statement earnings net sales total costs expenses earnings continuing operations discontinued operations net lossearnings net gain disposal net earnings basic earnings per common share continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings per common share continuing operations discontinued operations net earnings net gain disposal net earnings balance sheet december assets current assets cash cash equivalents marketable securities current assets total current assets assets total assets liabilities current liabilities liabilities longterm debt total liabilities stockholders equity total liabilities stockholders equity bristolmyers squibb company notes consolidated financial statements continued note alliances investments sanofisynthelabo company agreements sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operates framework two geographic territories one americas australia europe asia two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place company acts operating partner territory covering americas principally united states canada puerto rico latin american countries australia owns majority controlling interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded sales territory comarketing countries germany italy spain greece million million million sanofi acts operating partner territory covering europe asia owns majority financial controlling interest territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million company sanofi formed alliance copromotion irbesartan part company contributed irbesartan distribution rights united states sanofi paid company total million company accounts transaction sale interest license defers amortizes million income expected useful life license approximately eleven years company amortized income million million otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify aripiprazole treatment schizophrenia total milestone payments made otsuka december million million expensed acquired inprocess research development million capitalized payments amortized remaining life agreement approximately years company began copromoting product otsuka united states puerto rico november company also copromote product several european countries marketing approval received european authorities revenue earned otsuka ships product title passes customer company records alliance revenue share net sales copromotion countries records expenses related product company also exclusive right sell abilify number countries europe latin america asia countries sales commence company record net sales related cost sales company recorded revenue abilify million million imclone november company purchased million shares imclone per share million represented approximately imclone shares outstanding prior companys commencement public tender offer imclone shares transaction accounted using equity method accounting imclone biopharmaceutical company focused developing targeted cancer treatments include growth factor blockers cancer vaccines antiangiogenesis therapeutics equity investment imclone part strategic agreement company imclone also includes arrangement codevelop copromote cancer drug erbitux series payments originally totaling billion company paid imclone milestone payment million december imclone announced us food drug administration fda refused accept filing biologics license application bla submitted imclone erbitux bla submitted gain marketing approval treat irinotecanrefractory colorectal carcinoma march agreement imclone revised reduce total payments million billion revised agreement company paid imclone million march million march million march approval erbitux fda additional million upon achievement second milestone million paid imclone march million expensed inprocess research development first quarter remaining million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone also revised agreement company pay imclone distribution fee based flat rate bristolmyers squibb company notes consolidated financial statements continued note alliances investments continued product net revenues north america company purchase commercial requirements bulk erbitux imclone price equal actual manufacturing cost plus terms revised agreement continue fourth quarter company recorded pretax charge approximately million comprised million writeoff acquired process research development related equity investment million writeoff portion million milestone payment made remaining million million milestone payment recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquired inprocess research development charge related three oncology research projects phase later stage development one research project erbitux amount determined identifying research projects areas technological feasibility established alternative future use projected fda approval dates used years time company expected projects begin generate cash flows cost complete projects estimated million research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda approval purchase price allocation resulted million patent technology intangible assets amortized weightedaverage useful lives years approximately million goodwill amortized million paid equity investment million milestone payment million million expensed acquired process research development remaining million recorded equity investment additional million added investment primarily acquisition costs resulting carrying value million december third quarter company recorded pretax charge earnings million temporary decline market value imclone based decline value imclones shares fair value equity investment imclone used record impairment determined based market value imclone shares september total equity investment imclone december million compared million december per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december closing market price imclone shares march per share company recorded million net loss share imclones losses included million loss million related imclones restatement results final reporting full year first quarter results company recorded million net loss share imclones losses amortization previously capitalized milestone payments company records share results equity net income affiliates consolidated statement earnings february fda approved resubmitted bla erbitux erbitux treatment patients epidermal growth factor receptor egfr expressing metastatic colorectal cancer failed irinotecanbased regimen combination irinotecan monotherapy patients intolerant irinotecan bristolmyers squibb company notes consolidated financial statements continued note alliances investments continued summary financial information following summarized financial information companys equity investments imclone joint venture sanofi europe asia dollars millions revenues gross profit net income current assets noncurrent assets current liabilities noncurrent liabilities information includes imclone data date investment november bristolmyers squibb company notes consolidated financial statements continued note restructuring items activities company recorded pretax restructuring charges million relating downsizing streamlining worldwide operations rationalization worldwide manufacturing operations charge million primarily relates employee termination benefits approximately employees including manufacturing administrative sales personnel europe north america asia central america items million relate primarily relocation expenses result consolidation research facilities charges partially offset adjustment due changes estimates prior period reserves million principally due higher anticipated proceeds disposal assets reduced separation costs company expects complete restructuring activities addition company recorded million asset impairments accelerated depreciation relating rationalization manufacturing operations cost products sold following table presents detail provision restructuring items operating segment type company allocate restructuring charges business segments employee employee termination exit terminations benefits costs items total pharmaceuticals healthcare subtotal reduction reserves changes estimates provision restructuring items company also recorded million research development related upfront payments four licensing agreements allocated business segments activities company recorded pretax restructuring charges million relating reduction elimination nonstrategic research efforts well consolidation research facilities workforce reductions downsizing streamlining worldwide operations charge million relates employee termination benefits approximately employees including research manufacturing sales administrative personnel million represents asset writedowns including million impairment charge companys investment deltagen million exit costs closure facilities related expenses charges offset adjustment prior period restructuring reserves million million due lower expected separation costs million due higher anticipated proceeds disposal assets previously written restructuring million projects cancelled addition million adjustment cost products sold made reflect reversal inventory reserves associated cancelled projects company substantially completed restructuring activities addition million accelerated depreciation relating planned shutdown research facilities united states included research development expense million inventory writeoffs associated projects included cost products sold bristolmyers squibb company notes consolidated financial statements continued note restructuring items continued following table presents detail provision restructuring items operating segment type company allocate restructuring charges business segments employee employee termination asset write exit terminations benefits downs costs total dollars millions pharmaceuticals nutritionals healthcare corporateother subtotal reduction reserves changes estimates provisions restructuring items activities company recorded pretax restructuring charges million restructuring programs included termination benefits asset writedowns costs implemented downsize streamline operations rationalize manufacturing facilities terminate certain sales force research contract obligations actions substantially completed charge million relates employee termination benefits employees result companywide restructuring effort downsize streamline operations impacted virtually areas including sales force manufacturing administrative research personnel additional charges include million termination contract sales force million exit costs primarily related costs associated closure certain manufacturing operations charge also included million writedown fixed assets primarily related exit nutritionals business eastern europe closure pharmaceutical production facility united states closure research facility france items million relate costs associated product recall restructuring charges partially offset reversal million result change estimate relating separation costs cancellation projects previously provided additional costs associated restructuring projects include million sales deductions customer charge backs relating abandonment nonstrategic pharmaceutical product lines included reduction sales million related inventory writeoffs included cost products sold following table presents detail provision restructuring items operating segment type company allocate restructuring charges business segments employee asset employee termination write exit terminations benefits downs costs items total dollars millions pharmaceuticals nutritionals healthcare corporateother subtotal reduction reserves changes estimates provision restructuring items bristolmyers squibb company notes consolidated financial statements continued note restructuring items continued rollforward restructuring charges spending liabilities associated prior current actions follows employee termination exit cost liability liability total dollars millions balance december charges spending changes estimate balance december charges spending changes estimate balance december charges spending changes estimate balance december liabilities included accrued expenses consolidated balance sheet note acquisitions divestitures dupont pharmaceuticals acquisition october company acquired dupont pharmaceuticals e du pont de nemours company billion cash results dupont pharmaceuticals included consolidated financial statements date acquisition dupont pharmaceuticals primarily domestic pharmaceutical imaging product business focused research development acquisition financed proceeds issuance billion commercial paper issuance billion mediumterm notes internal cash flows following summary final allocation purchase price estimated fair values assets acquired liabilities assumed dollars millions current assets property plant equipment intangible assets acquired inprocess research development goodwill assets total assets acquired current liabilities restructuring liabilities acquisition liabilities longterm liabilities total liabilities assumed purchase price bristolmyers squibb company notes consolidated financial statements continued note acquisitions divestitures continued total intangible assets million amortized weightedaverage useful lives include core developed technology million years weightedaverage useful life respectively patents million year weightedaverage useful life goodwill million assigned pharmaceuticals segment total amount million expected deductible tax purposes year period time acquisition billion purchase price allocated acquired inprocess research development charged earnings fourth quarter charge associated five research projects amount determined identifying research projects technological feasibility established alternative future use two projects terminated three remaining projects two clinical stage one preclinical currently proceeding research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required fda approval connection acquisition company recorded million restructuring liabilities result severance relocation workforce elimination duplicate facilities contract terminations costs recognized company liability assumed acquisition date resulting additional goodwill liabilities consisted million employee termination benefits approximately employees million related closure facilities million contract terminations million originally recorded accrued expenses reduced million december million december million end reduction balance due cash payments million adjustment reverse previously recorded liabilities million corresponding reduction goodwill adjustment primarily due lower expected separation costs contract termination expenses facilities exit costs related acquisition reduction balance due cash payments million following unaudited pro forma financial information presents results acquisition occurred beginning restated year ended december dollars millions except per share data net sales net earnings earnings per sharebasic earnings per sharediluted unaudited pro forma results prepared comparative purposes include certain adjustments additional amortization expense result identifiable intangible assets arising acquisition increased interest expense acquisition debt exclude acquired inprocess research development charge related dupont pharmaceuticals acquisition pro forma net earnings earnings per share amounts include billion gain sale clairol pro forma results necessarily indicative either results operations actually would resulted acquisition effect beginning respective periods future results company completed sale two branded products moisturel duricef resulted pretax gain million company completed sale three pharmaceutical products corzide delestrogen florinef licensing rights corgard united states estrace tablets apothecon commodity business solage viactiv product lines resulted pretax gain million bristolmyers squibb company notes consolidated financial statements continued note discontinued operations company completed sale clairol procter gamble cash proceeds approximately billion sale resulted pretax gain billion billion taxes included gain disposal discontinued operations addition company spun zimmer holdings inc zimmer taxfree distribution resulting common stock dividend million company resolved several postclosing matters associated previously discontinued businesses resulting increase million gain disposal clairol million credit related reduction tax contingency reserve related spinoff zimmer million credit retained earnings related adjustment zimmer pension liability affecting spinoff zimmer net sales earnings discontinued operations follows dollars millions net sales earnings income taxes income taxes net earnings discontinued operations net earnings million reflected statement earnings primarily reflects reduction tax contingency reserve related spinoff zimmer consolidated statement cash flows includes clairol zimmer businesses date disposition company uses centralized approach cash management financing operations accordingly company allocate debt businesses cash flows operating investing activities principally investing discontinued operations years ended december million billion including approximately billion proceeds sale clairol respectively bristolmyers squibb company notes consolidated financial statements continued note earnings per share numerator basic diluted earnings per share net earnings available common stockholders denominator basic earnings per share weighted average number common shares outstanding period denominator diluted earnings per share weighted average shares outstanding adjusted effect dilutive stock options computations basic earnings per common share diluted earnings per common share follows year ended december restated restated millions except per share amounts earnings continuing operations discontinued operations net earnings net gain disposal net earnings basic average common shares outstanding earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted average common shares outstanding conversion convertible debt bonds incremental shares outstanding assuming exercise dilutive stock options earnings continuing operations discontinued operations net earnings net gain disposal net earnings weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million net earnings includes interest expense added back assumed conversion convertible debt common shares bristolmyers squibb company notes consolidated financial statements continued note expense net components expense net year ended december restated restated dollars millions interest expense interest income foreign exchange transaction loss net net expense net interest expense primarily related issuance billion debt billion commercial paper conjunction dupont pharmaceuticals imclone transactions addition interest expense reduced net interestrate swap gains million million respectively interest income relates primarily cash cash equivalents investments marketable securities bristolmyers squibb company notes consolidated financial statements continued note income taxes components earnings loss continuing operations minority interest income taxes year ended december restated restated dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december restated restated dollars millions current us nonus deferred us nonus companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes restated restated dollars millions earnings continuing operations minority interest income taxes us statutory rate effect operations ireland puerto rico switzerland state local taxes changes estimate contingent tax matters nondeductible reserves foreign effective tax rate continuing operations increased due primarily decrease effective tax rate benefit operations ireland puerto rico switzerland provisions certain nondeductible litigation reserves increase estimates contingent tax matters compared bristolmyers squibb company notes consolidated financial statements continued note income taxes continued components current noncurrent deferred income tax assets liabilities december restated dollars millions acquired inprocess research development intercompany profit inventory items foreign tax credit carryforward legal settlement restructuring acquisition divestiture reserves deferred income alternative minimum tax credit carryforward charitable contribution carryforward state tax net operating loss carryforward foreign net operating loss credit carryforward sales returns allowances research experimentation tax credit carryforward postretirement pension benefits depreciation deferred foreign currency gainloss net valuation allowance deferred tax assets net recognized deferred income tax assets current deferred income tax assets noncurrent us foreign income taxes payable liabilities noncurrent valuation allowance million december relates million foreign state net deferred tax assets million foreign state net operating loss tax credit carryforwards company currently believes likely remain unrealized future income taxes paid year million million million respectively current tax benefit realized upon exercise stock options charged capital excess par value stock amounted million million million respectively company settled us federal income tax returns internal revenue service irs us federal income taxes provided substantially unremitted earnings nonus subsidiaries since managements practice intent indefinitely postpone remittance total amount net unremitted earnings nonus subsidiaries approximately billion december company establishes liabilities possible assessments taxing authorities resulting known tax exposures amounts represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known december certain tax contingencies liabilities established although company reasonably estimate possible amount contingency possible contingencies could material effect changes estimates related contingent tax matters included rate reconciliation year ended december company recognized income tax benefit million due settlement certain prior year tax matters determination company expected settlement tax litigation bristolmyers squibb company notes consolidated financial statements continued note income taxes continued also company reorganized structure ownership many nonus subsidiaries principal purpose reorganization facilitate companys ability efficiently deploy financial resources outside united states company believes reorganization transactions generally taxfree inside outside united states possible however taxing authorities particular jurisdictions could assert tax liabilities arising reorganization transactions operations reorganized subsidiaries reasonably possible predict whether taxing authority assert tax liability reasonably estimate possible loss range loss respect asserted tax liability company would vigorously challenge assertion believes would prevail assurance result company prevail final non appealable determinations possible impact could material note receivables major categories receivables follow december dollars millions accounts receivabletrade accounts receivablemiscellaneous less allowances bad debts receivables net note inventories major categories inventories follow december restated dollars millions finished goods work process raw packaging materials consignment inventory bristolmyers squibb company notes consolidated financial statements continued note consignment significant portion companys us pharmaceuticals sales made wholesalers april company disclosed experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers company accounts certain sales pharmaceutical products cardinal health inc cardinal mckesson corporation mckesson using consignment model based part relationship amount incentives offered wholesalers amount inventory held wholesalers company determined shipments product cardinal shipments product mckesson met consignment model criteria set forth note accounting policiesrevenue recognition july july respectively case continuing end period thereafter accordingly consignment model required applied shipments prior respective periods company recognized revenue respect sales cardinal mckesson upon shipment product although company generally views approximately one month supply desirable level wholesaler inventory goforward basis level wholesaler inventory representative industry average applying consignment model sales cardinal mckesson company defined inventory excess wholesalers ordinary course business inventory level inventory two weeks three weeks supply respectively based levels inventory cardinal mckesson required used basis negotiation incentives granted march company entered distribution agreement mckesson provision warehousing order fulfillment services companys oncology therapeutics network otn specialty distributor anticancer medicines related products terms agreement mckesson purchases oncology products service otns fulfillment needs number vendors including company subsequent shipment product mckesson company significant continuing involvement transaction including marketing product enduser invoicing customer collecting receivables customer behalf mckesson addition otn keeps credit risk responsible shipping costs customer company accounts sales oncology products mckesson using consignment model defers recognition revenue products sold mckesson transactions resulted deferred revenue million million december respectively company recognized previously recorded deferred revenue net sales net rebates returns adjustments approximately million million respectively bristolmyers squibb company notes consolidated financial statements continued note property plant equipment major categories property plant equipment follow december restated dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest included categories property plant equipment shown company capitalized interest million million years ended december respectively note goodwill changes carrying amount goodwill years ended december follows pharmaceuticals nutritionals healthcare segment segment segment total dollars millions balance december purchase accounting adjustments change exit cost estimate purchase price allocation adjustments balance december restated bristolmyers squibb company notes consolidated financial statements continued note intangible assets intangible assets major asset class follows december dollars millions patentstrademarks licenses technology less accumulated amortization net carrying amount amortization expense intangible assets majority included costs products sold years ended december million million million respectively expected amortization expense next five years related current balance intangible assets follows years ending december dollars millions bristolmyers squibb company notes consolidated financial statements continued note shortterm borrowings longterm debt included shortterm borrowings amounts due foreign banks million million current installments longterm debt million million december respectively us commercial paper outstanding december us commercial paper outstanding december million average interest rate commercial papers issued fully repaid december proceeds commercial paper issuance used general corporate purposes average interest rates international shortterm borrowings current installments longterm debt outstanding december respectively compared respectively december december company two revolving credit facilities totaling billion aggregate support domestic commercial paper program facilities established september august respectively syndicate lenders extendable anniversary date consent lenders one revolving credit facilities certain financial covenants company compliance december borrowings outstanding revolving credit facilities december company unused shortterm lines credit foreign banks million million december respectively components longterm debt follows december dollars millions notes due notes due floating rate convertible debentures due notes due notes due debentures due debentures due debentures due yen notes due yen notes due euro interest yen principal term loan due industrial revenue bonds due yen notes due yen notes due variable rate industrial revenue bonds due capitalized leases company issued billion debt follows face value debt description dollars millions effective interest rates month libor convertible debt due callable strike price month libor notes due notes due yen notes due yen notes due yen notes due october company issued billion convertible debentures debentures pay interest quarterly annual rate equal month libor reset quarterly minus yield never less zero final maturity september debentures callable par time september issuer holders also redeem debentures par september fundamental change ownership bristolmyers squibb company notes consolidated financial statements continued note shortterm borrowings longterm debt continued company occurs bond initial conversion price conversion rate shares adjustable depending average closing prices applicable period maximum conversion rate shares company entered fixed floating interest rate swaps billion longterm debt cash payments interest million million million respectively payments due period later total years dollars millions longterm debt obligations included shortterm borrowings companys consolidated balance sheet balances represent outstanding nominal long term debt values december company provided financial guarantees form standby letters credit performance bonds majority standby letters credit us nuclear regulatory commission massachusetts department public health relating companys medical imaging manufacturing operations insurance companies support thirdparty liability programs performance bonds relate sale company product various foreign ministries health middle east company believes significant majority guarantees expire without funded amounts obligations presented following table expiration period less total year years dollars millions standby letters credit performance bonds guarantees total commercial commitments bristolmyers squibb company notes consolidated financial statements continued note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock capital excess common shares treasury cost treasury par value restricted issued shares stock stock stock dollars millions balance december issued pursuant stock plans options conversions preferred stock amortization lapses restricted stock purchases balance december issued pursuant stock plans options conversions preferred stock amortization lapses restricted stock purchases balance december issued pursuant stock plans options conversions preferred stock amortization lapses restricted stock balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share accumulated balances related component comprehensive income loss follows accumulated foreign currency available sale deferred loss minimum pension comprehensive translation securities effective hedges liability adjustment incomeloss dollars millions balance december restated comprehensive income loss balance december restated comprehensive income loss balance december restated comprehensive income loss balance december company expects recognize million deferred hedging losses net earnings next twelve months bristolmyers squibb company notes consolidated financial statements continued note stockholders equity continued stock compensation plans companys stock incentive plan officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price plan also provides granting performancebased stock options certain key executives terms stock incentive plan authorized shares include outstanding shares per year well number shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise shares available grant prior year granted year shares cancelled forfeited expired also available future grant plan incorporates companys longterm performance awards addition stock incentive plan provides granting shares common stock key employees subject restrictions continuous employment restrictions generally expire fiveyear period date grant compensation expense recognized restricted period december respectively restricted shares outstanding plan teamshare stock option plan fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized shares issuance plan individual grants generally become exercisable evenly third fourth fifth anniversary grant date maximum term years options shares exercised plan december fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model following assumptions dividend yield volatility riskfree interest rate assumed forfeiture rate expected life years bristolmyers squibb company notes consolidated financial statements continued note stockholders equity continued stock option transactions shares common stock weighted average exercise price available shares option plans plan plan balance december authorized granted granted result zimmer spinoff exercised lapsed balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december effective spinoff zimmer august unexercised bristolmyers squibb stock options held zimmer employees converted zimmer stock options remaining unexercised bristolmyers squibb stock options number stock options exercise price adjusted preserve intrinsic value stock options ratio exercise price fair value existed prior spinoff following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities remaining available future issuance number securities weighted average exercise equity compensation issued upon exercise price outstanding plans excluding outstanding options options warrants securities reflected warrants rights rights column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders bristolmyers squibb company notes consolidated financial statements continued note stockholders equity continued options outstanding options exercisable range weighted average weighted average number weighted average exercise prices number outstanding remaining contractual life exercise price exercisable exercise price december shares common stock reserved issuance pursuant stock plans options conversions preferred stock options related discontinued operations included amounts material bristolmyers squibb company notes consolidated financial statements continued note financial instruments company exposed market risk due changes currency exchange rates interest rates result company utilizes foreign exchange option forward contracts offset effect exchange rate fluctuations anticipated foreign currency transactions primarily intercompany inventory purchases expected occur within next two years company exposures net foreign currency denominated assets liabilities approximated million million december respectively primarily europe japan mexico canada foreign exchange option contracts forward contracts used hedge anticipated transactions companys primary foreign currency exposures relation us dollar euro canadian dollar japanese yen notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future cash flows effective portion changes fair value temporarily recorded comprehensive income recognized earnings hedged item affects earnings ineffective portion hedges reported earnings occurs fair value option forward contracts liabilities million million december respectively recorded accrued liabilities december fair value foreign exchange contracts based yearend currency rates blackscholes model case option contracts company uses derivative instruments part interest rate risk management policy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment company entered several fixed floating interest rate swap contracts several financial institutions notional amounts swaps billion billion december respectively accordance sfas accounting derivative instruments hedging activities company recognized net reduction interest expense million million respectively reflects benefit lower floating rate obtained swap compared fixed rate underlying debt swap contracts well underlying debt hedged recorded fair value resulted increase current assets longterm debt million million december respectively swap contracts generally held maturity company use derivative financial instruments speculative purposes company reclassified losses million million comprehensive income earnings majority classified cost products sold gain million reclassified comprehensive income income expenses carrying amount companys financial instruments includes cash cash equivalents marketable securities accounts receivable accounts payable approximates fair value december longterm debt noted difference fair value carrying value material bristolmyers squibb company notes consolidated financial statements continued note segment information company organized pharmaceutical company related healthcare businesses four reportable segmentspharmaceuticals otn nutritionals healthcare pharmaceuticals segment comprised global pharmaceutical international excluding japan consumer medicines businesses otn segment specialty distributor anticancer medicines related products otn previously included pharmaceuticals segment met quantitative thresholds reportable segment accordingly prior periods reclassified conform current year presentations nutritionals segment consists mead johnson primarily infant formula business healthcare segment consists convatec medical imaging consumer medicines united states japan businesses companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession three wholesalers accounted approximately respectively companys total net sales sales wholesalers accounted respectively companys total net sales three wholesalers accounted approximately companys total net sales sales concentrated pharmaceuticals segment worldwide sales selected products product categories follows restated restated dollars millions pharmaceuticals pravachol plavix taxol paraplatin avaproavalide sustiva monopril glucovance glucophage xr zeritzerit er coumadin abilify total revenue videxvidex ec tequin glucophage ir serzone reyataz buspar nutritionals infant formulas healthcare ostomy cardiolite wound therapeutics bristolmyers squibb company notes consolidated financial statements continued note segment information continued business segments earnings minority net sales interest income taxes yearend assets restated restated restated restated restated dollars millions pharmaceuticals oncology therapeutics network nutritionals healthcare total segments corporateother total corporateother principally consists interest income interest expense certain administrative expenses allocations business segments certain corporate programs corporateother also includes gain sales businessesproduct lines million million respectively accelerated depreciation million termination benefits exit costs million million respectively asset write impairment charges million million respectively upfront payments licensing agreements million downsized rationalized operations facilities million litigation charges net million million million respectively also includes million asset impairment charge imclone pharmaceuticals segment includes charge acquired inprocess research development million million respectively additionally pharmaceuticals includes litigation settlement income million upfront payment licensing agreement million million accelerated depreciation assets manufacturing facilities north america expected closed end million charge asset impairment million charge relocation expenses million charge retention bonus benefits also million deductions customer chargebacks related abandoned product lines included reduction net sales recorded corporateother assets include cash cash equivalents marketable securities goodwill certain assets capital expenditures depreciation dollars millions pharmaceuticals oncology therapeutics network nutritionals healthcare total segments corporateother total bristolmyers squibb company notes consolidated financial statements continued note segment information continued geographic areas net sales yearend assets restated restated restated dollars millions united states europe middle east africa western hemisphere pacific total note leases minimum rental commitments noncancelable operating leases primarily real estate effect december years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan funding policy contribute amounts provide current service fund past service liability plan benefits based primarily years credited service participants compensation plan assets consist principally equity fixed income securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside united states cost companys deferred benefits postretirement benefit plans included following components pension benefits benefits restated restated dollars millions dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets net amortization deferral net periodic benefit cost curtailments settlements total net periodic benefit cost company elected defer recognition medicare prescription drug improvement modernization act time accumulated postretirement benefit obligation net periodic postretirement benefit cost reflect effect act retiree medical plan specific authoritative guidance accounting federal subsidy pending fasb guidance issued could require change previously reported information bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued changes benefit obligations plan assets december companys defined benefit postretirement benefit plans pension benefits benefits restated restated dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements transfer dupont pharmaceuticals actuarial loss plan amendments benefits paid exchange rate losses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements transfer dupont pharmaceuticals transfer benefits paid exchange rate gains fair value plan assets end year funded status unamortized net obligation adoption unrecognized prior service cost unrecognized net actuarial loss net amount recognized amounts recognized balance sheet consist prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive income net amount recognized several plans underfunded accrued benefit obligations exceeded accrued benefit liabilities december additional minimum liabilities established increase accrued benefit liabilities values underfunded accrued benefit obligations totaled million million december respectively us unfunded benefit equalization plan us underfunded key international plan plans uk japan canada belgium additional minimum liability offset creation million intangible asset charges comprehensive income included stockholders equity million million december respectively accumulated benefit obligation defined benefit pension plans million million december respectively bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued information pension plans accumulated benefit obligations excess plan assets december restated dollars millions projected benefit obligation accumulated benefit obligation fair value plan assets attributable primarily unfunded us benefit equalization plan several plans international markets unfunded us benefit equalization plan provides pension benefits employees compensation irs limits funded taxadvantaged manner additional information pertaining companys pension postretirement plans pension benefits benefits restated restated dollars millions increase minimum liability included comprehensive income weightedaverage assumptions used determine benefit obligations december pension benefits benefits restated restated discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december pension benefits benefits restated restated discount rate expected longterm return plan assets rate compensation increase companys expected longterm rate return us pension plan assets target asset allocation public equity us international private equity fixed income approximated applying expected returns public equity private equity fixed income target allocation actual historical returns also relevant annualized returns periods ended december years years years us pension plan assets represented total company pension plan assets december disclosed total company expected return assets us pension plans due impact international pension plans typically employ less aggressive asset allocation expected return disclosed benefits relevant assets invested manner us pension plan assets international plan assets bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued assumed health care cost trend rates december health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage point increase point decrease dollars millions effect total service interest cost effect postretirement benefit obligation companys asset allocation pension postretirement benefits december pension benefits benefits restated restated public equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments diversified within three major asset categories us equity passively managed otherwise investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company common stock represents less plan assets december assets postretirement benefits commingled us pension plan assets therefore investment strategy identical described us pension plans contributions result improved investment returns significant contributions recent years current plan make cash contributions us pension plans significant tax deductible contributions likely allowed irs rules minimum contributions required contributions made us pension plans company may make taxdeductible contributions h account retiree medical benefits equal portion pension normal cost contributions international pension plans expected million range bristolmyers squibb company notes consolidated financial statements continued note pension postretirement benefit plans continued estimated future benefit payments following benefit payments reflect expected future service appropriate expected paid pension benefits benefits dollars millions years savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies various lawsuits claims proceedings investigations pending company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement employee retirement income security act amended erisa pricing sales marketing practices environmental health safety matters product liability insurance coverage significant matters described fourth quarter company established reserves liabilities million comprised million relation wholesaler inventory issues certain accounting matters discussed securities matters million relation pharmaceutical pricing sales marketing practices discussed pricing sales promotional practices litigation investigations possible time reasonably assess final outcome matters accordance gaap company determined amounts represent minimum expected probable losses respect groups matters eventual losses related matters may exceed reserves impact either one groups matters could material company believe topend range losses estimated exception accruals taxol buspar environmental product liability proceedings company established reserves matters described assurance increase scope matters future lawsuits claims proceedings investigations material management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity plavix litigation companys us territory partnership alliance sanofi plaintiff two pending patent infringement lawsuits instituted u district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v dr reddys laboratories ltd dr reddys laboratories inc cv rws similar proceedings involving plavix also instituted outside united states suits filed march may respectively based us patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix us patent discloses claims among things use clopidogrel prevent secondary ischemic event plaintiffs later withdrew patent lawsuit plaintiffs infringement position based defendants filing abbreviated new drug application anda fda seeking approval sell generic clopidogrel prior expiration composition matter patent defendants responded alleging patent invalid andor unenforceable cases consolidated discovery fact discovery closed october teva pharmaceuticals usa teva generic drug manufacturer filed anda fda claiming patent relating plavix invalid two others infringed teva none patents involved pending patent infringement litigation involving plavix teva filing challenge patent issue plavix litigation therefore expected impact litigation appear teva intends commercialize generic form plavix prior expiration termination patent issue litigation although assurance continue case net sales plavix approximately billion expected grow substantially next several years company anticipates revenue growth important factor offsetting expected decreases sales companys products recently experience exclusivity losses period currently company expects plavix market exclusivity united states composition matter patent plavix found infringed invalid andor unenforceable district court level fda could approve defendants andas sell generic clopidogrel generic competition plavix could begin company exhausted appeals generic competition would likely result substantial decreases sales plavix united states although plaintiffs intend vigorously pursue enforcement patent rights plavix possible time reasonably assess outcome lawsuits company prevail lawsuits timing potential generic competition plavix however generic competition occur company believes unlikely occur sometime year also possible reasonably estimate impact lawsuits company however loss market exclusivity plavix subsequent development generic competition would material companys sales plavix results operations cash flows could material financial condition liquidity bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued vanlev litigation april may june company former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd named defendants number class action lawsuits alleging violations federal securities laws regulations actions consolidated one action us district court district new jersey plaintiff claims defendants disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability product vanlev period november april may plaintiff submitted amended complaint adding allegations company present chairman board chief executive officer peter r dolan former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability vanlev period april march number related class actions making essentially allegations also filed us district court southern district new york actions transferred us district court district new jersey company filed motion partial judgment favor based upon pleadings plaintiff opposed motion part seeking amend complaint including another attempt expand proposed class period court ruled companys motion dismiss plaintiffs motion leave amend discovery ongoing plaintiff purports seek compensatory damages costs expenses behalf shareholders possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material securities matters period march may company number current former officers named defendants number securities class action suits suits variously alleged violations federal securities laws regulations connection three different matters vanlev discussed sales incentives wholesaler inventory levels imclone imclones product erbitux discussed allegations concerning vanlev transferred us district court district new jersey consolidated action pending remaining actions consolidated pending us district court southern district new york plaintiffs filed consolidated class action complaint april company certain current former officers alleging class period october march consolidated class action complaint alleges violations federal securities laws connection among things companys investment relationship imclone imclones product erbitux certain accounting issues addressed restatement including issues related wholesaler inventory sales incentives establishment reserves accounting certain asset sales plaintiffs seek compensatory damages costs expenses august company moved dismiss consolidated class action complaint plaintiffs opposed companys motion dismiss company replied motion remains pending court discovery matter stayed pursuant private securities litigation reform act addition action filed early october new york state court making similar factual allegations asserting variety claims including among others common law fraud negligent misrepresentation discovery taken matter january company moved dismiss complaint beginning october number companys current former officers directors named defendants three shareholder derivative suits pending us district court southern district new york number companys current former officers directors named defendants three shareholder derivative suits filed period march may us district court district new jersey july us district court district new jersey ordered three shareholder derivative lawsuits filed court transferred us district court southern district new york subsequently us district court southern district new york ordered six federal shareholder derivative suits consolidated plaintiffs filed consolidated amended verified shareholder complaint certain members board directors current former officers pricewaterhousecoopers pwc companys independent auditors company nominal defendant consolidated amended complaint alleges among things violations federal securities laws breaches fiduciary duty certain individual defendants connection companys conduct concerning among things safety efficacy commercial viability vanlev discussed companys sales incentives certain wholesalers inventory levels wholesalers companys investment bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued relations imclone imclones product erbitux alleged anticompetitive behavior connection buspar taxol lawsuit also alleges malpractice negligent misrepresentation negligence pwc plaintiffs seek restitution rescission certain officers directors compensation alleged improper insider trading proceeds injunctive relief fees costs expenses contribution certain officers alleged liability consolidated securities class action pending us district court southern district new york discussed contribution indemnification pwc discovery taken matter december company moved dismiss consolidated amended complaint two similar actions pending new york state court plaintiffs seek equitable relief damages costs attorneys fees sec us attorneys office grand jury district new jersey investigating activities company certain current former members companys management connection wholesaler inventory issues referenced certain accounting issues company cooperating investigations possible time reasonably assess final outcome litigations investigations reasonably estimate possible loss range loss respect litigations investigations company producing documents actively cooperating investigations investigations could result assertion civil andor criminal claims company andor current former members companys management company prevail final nonappealable determinations litigations investigations impact could material erisa litigation december first quarter company others named defendants five class actions brought erisa us district courts southern district new york district new jersey actions consolidated southern district new york caption bristolmyers squibb co erisa litigation cv amended consolidated complaint alleging class period january march served august amended consolidated complaint brought behalf four named plaintiffs putative class consisting participants bristolmyers squibb company savings investment program savings planand beneficiaries whose benefit savings plan held andor acquired company stock time class period excluding defendants heirs predecessors successors assigns named defendants company bristolmyers squibb company savings plan committee committee thirteen individuals presently serve committee served committee recent past charles heimbold jr peter r dolan past present chief executive officer respectively company amended consolidated complaint generally alleges defendants breached fiduciary duties erisa class period among things continuing offer company stock fund company stock investment alternatives savings plan continuing invest company matching contributions company stock fund company stock failing disclose investments company stock allegedly imprudent savings plans purchases company stock january alleged transactions prohibited erisa finally defendants heimbold dolan alleged breached fiduciary duties erisa failing monitor actions committee erisa claims predicated upon factual allegations similar raised securities matters concerning among things safety efficacy commercial viability vanlev companys sales incentives certain wholesalers inventory levels wholesalers companys investment relations imclone imclones product erbitux alleged anticompetitive behavior connection buspar taxol significant discovery october company defendants moved dismiss amended consolidated complaint plaintiffs opposed motion dismiss defendants replied possible time reasonably predict final outcome reasonably estimate possible loss range loss respect consolidated litigation company prevail final nonappealable determinations matters impact could material pricing sales promotional practices litigation investigations company together number pharmaceutical manufacturers defendant several private class actions actions brought nevada montana attorneys general counties suffolk westchester rockland new york pending federal state courts relating pricing certain company products federal cases consolidated pretrial purposes caption pharmaceutical industry average wholesale price litigation mdl us district court district massachusetts awp multidistrict litigation bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued june court awp multidistrict litigation granted private plaintiffs motion leave file amended master consolidated complaint amended master complaint amended master complaint contains two sets allegations company first alleges companys many pharmaceutical manufacturers reporting prices certain drug products listed drugs companys case effect falsely overstating average wholesale price awp published industry compendia turn improperly inflated reimbursement paid medical providers others prescribed administered products second alleges company certain defendant pharmaceutical manufacturers conspired one another program called together rx card program fix awps certain drugs made available consumers program amended master complaint asserts claims federal rico antitrust statutes state consumer protection fair trade statutes amended master complaint brought behalf two main proposed classes divided subclasses persons entities forward directly paid portion price listed drug price calculated reference awp b contracted pharmacy benefit manager provide others drugs listed amended consolidated complaint persons entities forward paid reimbursed portion purchase price drug covered together rx card program based whole part awp company defendants moved dismiss amended master complaint grounds fails state claims applicable statutes motions denied february although court dismissed one plaintiffs claims failure plead cognizable rico enterprise accordingly company defendants required answer amended master complaint addition company engaged continue engage discovery private class actions awp multidistrict litigation nevada montana attorneys general complaints assert claims similar amended master complaint state law also assert claims name respective states alleged violations state medicaid fraud statutes nevada montana attorneys general cases originally commenced respective state courts later removed awp multidistrict litigation attorney general moved case remanded state court ground federal jurisdiction june court awp multidistrict litigation ruled nevada action company named remanded state court ground defendants joined original removal petition case proceeding nevada state court court retained jurisdiction montana case defendants moved dismiss montana second nevada case company named oral argument heard motion december ruling issued finally company defendant related state court proceedings commenced new york new jersey california arizona tennessee proceedings attorney general pennsylvania federal court proceedings commenced counties suffolk westchester rockland new york collectively new york counties awp cases proceedings transferred awp multidistrict litigation pretrial purposes although plaintiffs california arizona new jersey actions sought remand cases state courts california remand motions denied arizona remand motion granted remand motions remain pending new york counties awp cases allege rico claims similar made amended master consolidated complaint awp multidistrict litigation however claims behalf counties contributors new york states medicaid obligations defendants firstfiled suffolk county case moved dismiss amended complaint action oral argument heard motion december ruling issued respect case remanded arizona state court defendants filed motions dismiss stay hearing motions currently scheduled june merits discovery stayed cases preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect cases company prevail final nonappealable determinations litigations investigations impact could material company together number pharmaceutical manufacturers also received subpoenas document requests various government agencies seeking records relating pricing sales marketing practices best price reporting drugs covered medicare andor medicaid requests records come us attorneys office district massachusetts office inspector general department health human services conjunction civil division department justice office inspector general office personnel management conjunction us attorneys office eastern district pennsylvania several states addition request information come house committee energy commerce connection investigation committee bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued currently conducting medicaid best price issues finally company received civil investigative demand attorney general state missouri relating direct consumer advertising pravachol period company also received notice putative class action lawsuit involving issues filed february circuit court jackson county missouri kansas city captioned richard summers v bristolmyers squibb company company served complaint july company announced recently initiated internal review certain sales marketing practices review focuses whether practices comply applicable antikickback laws also includes analysis practices respect compliance best price reporting rebate requirements medicaid program certain us governmental programs reference medicaid rebate program applicable fda requirements company met representatives us attorneys office district massachusetts discuss review company received subpoena us attorneys office district massachusetts companys internal review expected continue resolution pending governmental investigations related matters company producing documents actively cooperating investigations could result assertion civil andor criminal claims company unable assess outcome reasonably estimate possible loss range loss respect investigations could include imposition fines penalties administrative remedies andor liability additional rebate amounts company prevail final non appealable determinations litigations investigations impact could material ctlaig litigation august repligen corporation repligen university michigan instituted lawsuit company us district court eastern district michigan suit alleged dr craig thompson formerly professor university michigan involved collaboration certain companys scientists thompsons activity collaboration made rightful inventor several patents company later obtained covering soluble forms ctla related methods use conducting trial september district court ruled repligen university michigan failed prove thompson made inventive contribution patents suit thus entitled added sole joint inventor companys patents repligen university michigan appealed district courts decision us court appeals federal circuit erbitux litigation october complaint filed yeda research development company ltd yeda imclone systems aventis pharmaceuticals inc us district court southern district new york action alleges seeks three individuals associated yeda also named coinventors us patent covers therapeutic combination egfr monoclonal antibody antineoplastic agents chemotherapeutic agents use treatment cancer yedas action successful yeda could position practice license others practice invention could result product competition erbitux might otherwise occur company party action unable predict outcome stage proceedings product liability litigation company party product liability lawsuits involving allegations injury caused companys pharmaceutical overthecounter medications majority lawsuits involve certain overthecounter medications containing phenylpropanolamine ppa companys serzone stadol ns prescription drugs addition lawsuits company also faces unfiled claims involving products ppa may yale university published results hemorrhagic stroke project concluded evidence suggestion ppa may increase risk hemorrhagic stroke limited population november fda issued public health advisory requested manufacturers ppacontaining products voluntarily cease manufacturing marketing time ppacontaining products manufactured sold company comtrex liquid gel formulations naldecon november company well manufacturers ppa containing products discontinued manufacture marketing ppa containing products allowed customers return unused product possession january company served first ppa lawsuit company currently defendant approximately personal injury lawsuits filed behalf approximately plaintiffs federal state courts throughout bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued united states majority lawsuits involve multiple defendants among claims plaintiffs allege ppa causes hemorrhagic ischemic strokes defendants aware risk failed warn consumers failed remove ppa products plaintiffs seek compensatory punitive damages federal cases transferred us district court western district washington phenylpropanolamine ppa products liability litigation mdl district court denied motions class certification class action lawsuits pending company litigation june district court issued ruling effectively limiting plaintiffs claims hemorrhagic ischemic strokes rulings favorable defendants included inadmissibility expert testimony cases alleging injuries occurring three days ingestion ppa containing product cases involving psychoses seizures cardiac injuries company expects dismissed additional cases products never used plaintiffs plaintiffs alleged injury occurred three days ingestion ppa containing product plaintiff suffered cardiac injuries psychoses serzone serzone nefazodone hydrochloride antidepressant launched company may canada march united states december company added black box warning serzone label warning potential risk severe hepatic events including possible liver failure need transplantation risk death within several months black box warning added package insert serzone number lawsuits including several class actions filed company plaintiffs allege company knew known hepatic risks posed serzone failed adequately warn physicians users risks seek compensatory punitive damages medical monitoring refunds costs purchasing serzone present company lawsuits behalf plaintiffs pending federal state courts throughout united states twenty four cases pending new york state court consolidated pretrial discovery addition approximately alleged unfiled claims injury associated serzone august federal cases transferred us district court southern district west virginia serzone products liability litigation mdl although discovery still early stage appears cases involve liver failure june district court dismissed class claims two class action complaints although number class action complaints filed company sought certification one personal injury classes remaining class action complaints seek certification personal injury classes january court issued order setting hearing class certification october addition cases filed united states three national class actions filed canada stadol ns stadol ns approved fda unscheduled opioid analgesic nasal spray february company asked fda schedule stadol ns schedule iv low potential abuse drug due postmarketing reports suggestive inappropriate use product october became schedule iv drug since company received number lawsuits involving stadol late number filed suits increased due newly passed tort reform legislation became effective january plaintiffs new suits previously asserted claims company alleged injuries company currently party cases pending behalf total approximately plaintiffs federal state courts throughout united states plaintiffs claim company committed fraud fda wrongfully promoted stadol ns nonaddictive plaintiffs allege company failed adequately warn addiction dependency risk associated use stadol ns addition lawsuits approximately alleged unfiled claims approximately active majority cases claims pending mississippi addition cases filed united states two class actions one individual case filed canada breast implant litigation company together subsidiary medical engineering corporation mec certain companies remains defendant number claims lawsuits alleging damages personal injuries various types resulting polyurethanecovered breast implants smoothwalled breast implants formerly manufactured mec related company vast majority claims company direct lawsuits resolved settlements trial likewise claims potential claims company registered nationwide class action settlement approved federal district court birmingham alabama revised settlement resolved revised settlement company established accruals respect breast implant product liability litigation company believes possible loss addition amounts accrued material company intends vigorously defend product liability lawsuits believes majority cases claims without merit possible time reasonably assess final outcome companys pending product liability lawsuits unfiled claims certainty management opinion ultimate disposition matters material adverse effect companys financial position company believes adequate selfinsurance reserves commercially available excess insurance cover potential loss related product liability cases claims bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued platinol litigation february class action complaint filed north shore hematologyoncology associates pc company us district court district columbia putative class action brought behalf direct purchasers platinol alleges company violated federal antitrust laws maintaining monopoly us market allegations focus companys actions concerning us patent patent including procurement patent submission information relating patent listing orange book initiation previous lawsuits potential generic manufacturers based patent plaintiffs seek declaratory judgment damages including treble damages company markets platinol exclusive patent licenses research corporation technologies rct federal trade commission ftc also opened investigation relating platinol matter settled entry consent decree effect april possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material taxol litigation number putative class actions brought company alleging antitrust consumer protection similar claims concerning companys actions obtain enforce patent rights relating taxol number state attorneys general brought similar claims certain insurers asserted similar claims without filing suits matters settled required court approval given final approval supervising court total amount settlements million amount million accrued remaining million accrued ftc also opened investigation relating taxol matter settled entry consent decree effect april additional case based allegations brought small generic drug manufacturer company moved dismiss case court granted motion july plaintiff sought reconsideration decision unsuccessful plaintiff filed notice appeal us court appeals seventh circuit possible time reasonably assess final outcome suit reasonably estimate possible loss range loss dismissal reversed dismissal reversed company prevail final nonappealable determination action impact could material buspar litigation number putative class actions brought company alleging antitrust consumer protection similar claims concerning companys actions obtain enforce patent rights relating buspar number state attorneys general brought similar claims certain insurers generic drug manufacturers chain drug stores asserted similar claims matters settled required court approval given final approval supervising court total amount settlements million amount million accrued million accrued remaining million accrued ftc also opened investigation relating buspar matter settled entry consent decree effect april environmental proceedings following discussion describes environmental proceedings governmental authority may involve potential monetary sanctions threshold prescribed specific sec rule civil action environmental claim could result significant liabilities updates ongoing matters resolution matters disclosed recent public filings summary environmental remediation costs bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued preliminary results internal audit performed companys facility hopewell nj indicate operations sites wastewater treatment plant related discharges may compliance new jersey water pollution control act implementing regulations terms companys discharge permits company reported findings new jersey department environmental protection njdep february currently engaged settlement discussions state none results audit suggest adverse impact public health company taken continue take corrective actions address identified deficiencies prevent future occurrences january njdep sent company approximately five companies information request letter relating site north brunswick township nj waste materials er squibb sons squibb wholly owned subsidiary bms may disposed fill material containing industrial waste heavy metals excess residential standards discovered fall expansion project north brunswick township high school school board township current owners site preparing submit workplan njdep asked company contribute cost remediation company discussions njdep site owners potentially responsible parties site investigation ongoing claims asserted company september njdep issued administrative enforcement directive notice new jersey spill compensation control act requiring company approximately companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river directive alleges company liable historically sent bulk waste former inland chemical company facility newark new jersey releases hazardous substances facility migrated newark bay continue adverse impact lower passaic river watershed subsequently us environmental protection agency usepa also issued notice letter us comprehensive environmental response compensation liability act cercla numerous partiesbut including bmsseeking cooperation study conditions substantially stretch passaic river subject njdeps directive usepa estimates study cost million study may also lead cleanup actions directed usepa army corps engineers extent liability either directive usepas notice letter yet determined although company believe bms caused contributed contamination lower passaic river watershed company informed njdep willing discuss allegations company njdep directive states responsible parties cooperate njdep may perform damage assessment restoration take civil action recover remedial costs treble damages administrative costs penalties october michigan department environmental quality mdeq sent company letter violation lov alleging unspecified period time emissions certain digestion tanks mead johnsons zeeland michigan facility exceeded applicable limit facilitys renewable operating air permit lov requires company take corrective action submit compliance program report although mdeq demanded fines penalties enforcement action could result penalties injunctive relief company contesting allegations lov july njdep advised squibb believed company violated clean air act failing comply prevention significant deterioration requirements connection replacement gas turbine companys cogeneration facility new brunswick new jersey facility december company settled matter njdep signing administrative consent order requires company submit permit application creating facilitywide emissions cap pay administrative fine approximately may environmental quality board puerto rico issued notice bristolmyers squibb alleging five violations federal resource recovery conservation act relating recordkeeping storage requirements hazardous wastes companys facility humacao based prior dealings eqb technical nature alleged violations company believes penalties imposed significant company one several defendants class action suit filed superior court puerto rico february residents alleging air emissions government owned operated wastewater treatment facility barceloneta caused respiratory ailments violated local air rules company believes wastewater discharges treatment facility material compliance terms companys permit company believes litigation resolved immaterial amount nevertheless suit still initial stage event adverse judgment companys ultimate financial liability could significantly greater anticipated bristolmyers squibb company notes consolidated financial statements continued note legal proceedings contingencies continued company also responsible various state federal foreign laws including cercla certain costs investigating remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties company estimates costs based information obtained usepa relevant agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties prp company accrues liabilities probable reasonably estimable company estimates share total future costs sites approximately million represents sum best estimates simple estimate reasonably made estimates minimums costs without taking account potential recoveries parties currently expected company paid less million excluding legal fees last five years investigation remediation matters including liabilities cercla onsite remediations although possible predict certainty outcome environmental proceedings ultimate costs remediation company believe reasonably possible expenditures company may incur excess existing reserves material adverse effect business financial position results operations indemnification officers directors companys corporate bylaws require extent permitted law company shall indemnify officers directors judgments fines penalties amounts paid settlement including legal fees appeals incurred connection civil criminal actions proceedings relates services company subsidiaries bylaws provide limit amount indemnification indemnification permitted case willful misconduct knowing violation criminal law improper personal benefit permitted laws state delaware company many years purchased directors officers insurance coverage cover claims made directors officers amounts types coverage varied period period dictated market conditions various excess policies provide additional coverage litigation matters regulatory actions described involve certain companys current former directors officers covered aforementioned indemnity applicable certain prior period insurance policies however certain indemnification payments may covered companys directors officers insurance coverage company predict certainty extent company recover insurers indemnification payments made connection litigation matters regulatory actions described july one companys insurers federal insurance company filed lawsuit new york supreme court company several current former officers members board directors seeking rescission alternative declarations allowing federal avoid payment certain directors officers insurance policies certain fiduciary liability insurance policies respect potential liability arising connection matters described vanlev litigation securities matters erisa litigation sections discovery taken matter october another companys insurers sr international business insurance co ltd sri informed company intended try avoid certain insurance policies issued company grounds alleged material misrepresentation nondisclosure initiated arbitration proceedings london england sri indicated intends rely upon allegations similar described securities matters section support avoidance action possible time reasonably assess final outcome matters reasonably estimate possible loss range loss respect matters company prevail final nonappealable determinations matters impact could material bristolmyers squibb company notes consolidated financial statements continued note subsequent events december company confirmed mead johnson wholly owned subsidiary company reached agreement novartis ag novartis sell novartis adult nutritional business terms agreement novartis acquire brands trademarks patents intellectual property rights mead johnson global adult medical nutrition business million including million contingent product conversion million upfront payment supply agreement transaction closed february pretax gain approximately million expected recorded first quarter adult nutritional products recorded sales million company announced january agreed acquire acordis specialty fibres acordis privately held company based united kingdom licenses patent rights supplies materials convatec wound therapeutics line transaction subject regulatory approval received transaction completed company expects record inprocess research development charge million million fda approved bla erbitux anticancer agent company developing partnership imclone february erbitux injection use combination irinotecan treatment patients egfrexpressing metastatic colorectal cancer refractory irinotecan based chemotherapy use single agent treatment patients egfrexpressing metastatic colorectal cancer intolerant irinotecan based chemotherapy accordance agreement company paid imclone march million milestone payment approval erbitux fda bristolmyers squibb company notes consolidated financial statements continued note selected quarterly financial data unaudited selected quarterly financial data set forth note revised reflect restatement discussion restatement see note restatement previously issued financial statements years ended december first quarter second quarter third quarter previously previously previously dollars millions except per share data reported restated reported restated reported restated net sales gross margin net earnings earnings per common share basic diluted dividends declared per common share cash cash equivalents marketable securities dollars millions except per share data net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities bristolmyers squibb company notes consolidated financial statements continued note selected quarterly financial data unaudited continued fourth quarter year dollars millions except per share data reported reported net sales gross margin net earnings earnings per common share basic diluted dividends declared per common share cash cash equivalents marketable securities fourth quarter year previously previously dollars millions except per share data reported restated reported restated net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities bristolmyers squibb company notes consolidated financial statements continued note selected quarterly financial data unaudited continued note earnings per share quarters may add amounts year period computed discrete basis includes litigation settlement charges million million second fourth quarters respectively first second third quarters include litigation settlement income million million million respectively first second third fourth quarters include provisions restructuring items million million million million respectively second third fourth quarters include reversals prior period restructuring items million million million respectively third fourth quarters include upfront payments licensing agreements million million respectively includes gain sale product lines million first quarter first third fourth quarters include writeoffs acquired inprocess research development million million million respectively second fourth quarters include provisions restructuring items million million respectively first third quarters include reversals prior period restructuring items million million respectively litigation settlement charges million million included first third quarters respectively also third quarter includes million asset impairment charge imclone principal corrections interim periods restatement discussed note restatement previously issued financial statements years ended december intercompany foreign exchange gains losses first quarter wic rebates accrual second quarter minority interest tax adjustment third quarter well intercompany foreign exchange gains losses income taxes vacation accrual third quarter common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year first quarter discontinued operations results included purchase price adjustment related clairol transaction million million net tax third quarter discontinued operations results included litigation provision million million net tax gain adjustment relating clairol transaction million million net tax fourth quarter discontinued operations results included million reduction provision income taxes due reduction tax contingency reserve related zimmer spinoff principal corrections interim periods restatement discussed note restatement previously issued financial statements years ended december intercompany foreign exchange gains losses third quarter goods transit adjustments provision income taxes fourth quarter report independent auditors board directors stockholders bristolmyers squibb company opinion consolidated financial statements listed index appearing item present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america addition opinion financial statement schedule listed index appearing item presents fairly material respects information set forth therein read conjunction related consolidated financial statements financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion described note restatement previously issued financial statements years ended december company restated previously issued financial statements described note accounting policies company changed method accounting business combinations goodwill arising transactions consummated subsequent june changed method accounting goodwill arising transactions consummated prior july impairment longlived assets pricewaterhousecoopers llp pricewaterhousecoopers llp philadelphia pennsylvania march item changes disagreements accountants accounting financial disclosure none item controls procedures company restating consolidated balance sheet december consolidated statements earnings cash flows comprehensive income retained earnings years ended december financial statements first second third quarters including comparable interim periods restatement discussion individual restatement adjustments see item financial statementsnote restatement previously issued financial statements years ended december december company carried evaluation supervision participation chief executive officer chief financial officer pursuant rule promulgated securities exchange act amended effectiveness design operation disclosure controls procedures making evaluation company considered matters relating restatement including actions taken company within past year identify enhance effectiveness disclosure controls procedures internal controls financial reporting completing restatement company continued identify implement actions improve effectiveness disclosure controls procedures internal controls financial reporting connection effort company substantially strengthened organization personnel senior financial control functions ii adopted rigorous policies procedures respect balance sheet review process iii focused internal audit function financial reporting controls iv engaged consultant assist evaluation documentation certain financial reporting disclosure processes throughout company v engaged consultant assist comprehensive detailed review certain companys tax reporting accounting addition request companys audit committee companys independent auditors performed extensive procedures respect companys interim financial information based auditors assessment companys risk profile expanded scope amount field work performed certain areas connection audit company actions contributed significantly company identifying additional errors relating prior periods reflected restatement march company restated financial statements three years ended december including corresponding interim periods first second quarters including comparable prior interim periods restatement connection audits restatement companys consolidated financial statements year ended december companys independent auditors pricewaterhousecoopers llp pwc identified communicated company audit committee two material weaknesses defined standards established american institute certified public accountants relating companys accounting public financial reporting significant matters initial recording management review oversight certain accounting matters addition time pwc identified communicated company audit committee reportable condition defined standards established american institute certified public accountants relating companys internal controls financial reporting income taxes connection audit companys consolidated financial statements year ended december pwc advised company audit committee reportable condition income tax accounting area remains company dedicated substantial resources improving controls accounting financial disclosure reporting auditors identified material weaknesses connection audit financial statements addition company devoted substantial resources towards remedying reportable condition relation taxes companys efforts strengthen financial internal controls continue company expects complete remediation reportable condition end based evaluation companys chief executive officer chief financial officer concluded evaluation date disclosure controls procedures reasonably designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified rules forms securities exchange commission described since evaluation date companys management internal controls significant changes internal controls factors could significantly affect internal controls part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item